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breast cancer screening, especially advantageous for women with dense breasts. While studies have
reported the benefits of DEM in breast cancer screening, thus far, no DEM-specific contrast agents have
been approved. Therefore, clinics use iodinated contrast agents, which can have suboptimal contrast in
DEM, short circulation half-life, and adverse effects on patients. Nanoparticle-based contrast agents can
be designed to address some of these limitations. This thesis explores different materials to develop
DEM-specific nanoparticle-based contrast agents with high contrast and biocompatibility. Based on
previous research highlighting elements that produce high DEM contrast, we explored materials such as
silver, tellurium, and molybdenum to develop DEM-specific nanoparticle-based contrast agents. First, 8
nm silver telluride nanoparticles (Ag2Te NPs) were developed as DEM-specific contrast agents. Ag2Te
NPs are composed of two DEM high-contrast generating materials and thus, provide superior contrast
than iodinated molecules, both in in vitro and in vivo settings. Additionally, by coating these with mPEGSH 5K, we prolonged their circulation, tumor accumulation, and colloidal stability while maintaining
biocompatibility. Next, to further improve the likelihood of clinical translation of Ag2Te NPs, we designed
them to be 3 nm in size to achieve renal clearance. These 3 nm Ag2Te NPs provided similar contrast and
biocompatibility to the larger Ag2Te NPs, even when studied for a longer term in vivo. Furthermore, 93% of
the injected dose was excreted from the main organs in 24 hours, 95% in 7 days, and 97% in 28 days. This
excretion is among the highest reported thus far for any nanoparticle type. Lastly, we developed 2 nm
molybdenum disulfide nanoparticles (MoS2 NPs) with different coatings and explored them as DEMspecific contrast agents. Our findings suggest that MoS2 NPs can produce higher contrast than iodinated
molecules and be biocompatible in vitro. Together, this work presents an advancement in the
development of DEM-specific contrast agents and their potential progression towards clinical translation.
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ABSTRACT
EXPLORING NOVEL MATERIALS TO BE USED AS DUAL-ENERGY MAMMOGRAPHY
CONTRAST AGENTS FOR BREAST CANCER DETECTION
Lenitza M. Nieves López
David P. Cormode

Dual-energy mammography (DEM) is a recently FDA-approved x-ray imaging
technology developed for breast cancer screening, especially advantageous for women
with dense breasts. While studies have reported the benefits of DEM in breast cancer
screening, thus far, no DEM-specific contrast agents have been approved. Therefore,
clinics use iodinated contrast agents, which can have suboptimal contrast in DEM, short
circulation half-life, and adverse effects on patients. Nanoparticle-based contrast agents
can be designed to address some of these limitations. This thesis explores different
materials to develop DEM-specific nanoparticle-based contrast agents with high contrast
and biocompatibility. Based on previous research highlighting elements that produce
high DEM contrast, we explored materials such as silver, tellurium, and molybdenum to
develop DEM-specific nanoparticle-based contrast agents. First, 8 nm silver telluride
nanoparticles (Ag2Te NPs) were developed as DEM-specific contrast agents. Ag2Te NPs
are composed of two DEM high-contrast generating materials and thus, provide superior
contrast than iodinated molecules, both in in vitro and in vivo settings. Additionally, by
coating these with mPEG-SH 5K, we prolonged their circulation, tumor accumulation,
and colloidal stability while maintaining biocompatibility. Next, to further improve the
likelihood of clinical translation of Ag2Te NPs, we designed them to be 3 nm in size to
achieve renal clearance. These 3 nm Ag2Te NPs provided similar contrast and
iii

biocompatibility to the larger Ag2Te NPs, even when studied for a longer term in vivo.
Furthermore, 93% of the injected dose was excreted from the main organs in 24 hours,
95% in 7 days, and 97% in 28 days. This excretion is among the highest reported thus
far for any nanoparticle type. Lastly, we developed 2 nm molybdenum disulfide
nanoparticles (MoS2 NPs) with different coatings and explored them as DEM-specific
contrast agents. Our findings suggest that MoS2 NPs can produce higher contrast than
iodinated molecules and be biocompatible in vitro. Together, this work presents an
advancement in the development of DEM-specific contrast agents and their potential
progression towards clinical translation.
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Chapter 1: Introduction to breast cancer, breast density, x-ray
imaging, dual-energy mammography, and nanoparticles as dualenergy mammography contrast agents for breast cancer screening

Parts of this chapter were adapted with permission from Wiley Interdiscip. Rev.: Nanomed.
Nanobiotechnol., 2020, 12, e1642 and Nanoscale, 2021, 13, 19306-19323.

1.1 Introduction
Breast cancer has the highest incidence rate among all cancers in women
worldwide. The 5-year survival rate of breast cancer patients depends on the stage at
which the disease is diagnosed, with those diagnosed at the localized stage having a
99% 5-year survival rate compared to only 28% for those diagnosed with metastasized
cancer. Mammography is the most commonly used imaging technique for breast cancer
and plays an important role in breast cancer detection. However, the ability of
conventional mammography to detect breast cancer can be highly affected by breast
density. Breast density is defined as the ratio of fibroglandular to adipose tissue in the
breast. When the breast density is high, the breast tissue in the mammogram has high
contrast and can often mask or make it challenging to discern malignant lesions.
Dual-energy mammography (DEM), or contrast-enhanced mammography, was
specifically designed to address this limitation. DEM can detect breast cancer,
regardless of breast density levels, with higher specificity (66% in DEM vs. 52% in
contrast-enhanced MRI) and comparable sensitivity to contrast-enhanced MRI (97%).
1

This imaging technique requires the administration of a contrast agent. Currently, no
commercially available contrast agents are specifically designed for DEM, and clinics
rely on iodinated, small molecule contrast agents used with computed tomography (CT).
However, these contrast agents have drawbacks that limit their application as DEM
contrast agents, such as relatively low contrast production and risk of adverse reactions
in some patients.
Nanoparticles (NPs) have been used as contrast agents for CT and other
imaging modalities and have been shown to possess numerous advantages compared
with iodinated, small molecule contrast agents. However, their exploration as DEM
contrast agents has been limited. Previous studies have shown that several elements
can produce high DEM contrast. Therefore, in this thesis, I describe the development of
NPs made of different DEM contrast generating materials and their potential use for this
application.
In this chapter, I will provide some background on breast cancer and the role of
breast density in this type of cancer. In addition, I will discuss the importance of
mammography and other imaging modalities for the detection of breast cancer and will
describe the principles of contrast generation. Next, I will introduce DEM, discuss the
principles of how it works, and its advantages. I will also discuss the use of iodinated
contrast agents and the advantages of NPs as x-ray contrast agents. I will then discuss
previous research on the DEM contrast generation of different materials, leading to my
thesis project. Lastly, I will introduce silver chalcogenide and transition metal
dichalcogenide NPs and, more specifically, silver telluride (Ag2Te) and molybdenum
disulfide (MoS2) NPs in their use as DEM contrast agents.
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1.2 Background
1.2.1 Breast cancer
1.2.1.1 Global incidence and mortality
Cancer is one of the leading causes of death worldwide and the second-leading
cause of death in the U.S. Among the types of cancer, breast cancer has the highest
incidence rate in women worldwide (Figure 1-1), representing 11.7% of all cancer
types.1 In the U.S., 284,200 new breast cancer cases were estimated in 2021 (30% of all
cancer types in females), with over 44,000 deaths among both females & males.2 The
probability of women developing breast cancer in their lifetime is 12.9%.2

Figure 1-1: Most common cancer incidence in females in each country in 2020. Figure
adapted with permission from reference 1.

While breast cancer survival has improved since the mid-1970s, with a 90%
current overall 5-year survival rate for women, this rate greatly depends on the stage of
3

the disease at diagnosis.2 If diagnosed at the localized or regional stage, the 5-year
survival rate remains relatively high at 99% and 86%, respectively. However, if the
disease is diagnosed when it has progressed to the distant (metastatic) stage, the 5-year
survival rate decreases to 28%. Therefore, early detection of the disease is crucial for
the 5-year survival rate of breast cancer in female patients.

1.2.1.2 Risk factors
Risk factors associated with breast cancer can be classified into modifiable and
non-modifiable. Non-modifiable factors include genetic variations which are mostly
inherited and are localized in genes such as BRCA1 or BRCA2, family history of breast
cancer, history of ductal or lobular carcinoma in situ, and high breast tissue density.3-5
Furthermore, certain reproductive factors can play an important role in breast cancer.
These reproductive factors include hormonal contraceptives, child-bearing age, lack of
breastfeeding, high endogenous estrogen or testosterone levels post-menopause, and
long menstrual periods.3-5 Modifiable factors include excess weight and weight gain, diet,
menopausal hormone therapy, alcohol consumption, and physical inactivity.3-5 Other
risk factors associated with breast cancer are age and sex, where older females tend to
have a higher risk.3

1.2.1.3 Breast density
As mentioned above, one of the non-modifiable breast cancer risk factors is
breast tissue density. Breast tissue density is the ratio between the fibroglandular and
adipose tissue in the breast. Breast density is currently classified, after a mammogram,
4

using the Breast Imagine Reporting and Data System (BI-RADS). Using this system,
breasts are classified into four main categories: A) almost entirely fatty, B) scattered
areas of fibroglandular density, C) heterogeneously dense, which may obscure some
small masses, and D) extremely dense, which lowers the sensitivity of mammography.6
Increased breast density is positively correlated to increased breast cancer risk.7,

8

Compared to breast density of 11-25%, those with 25-50% can have a 1.6 times higher
risk of developing breast cancer. In contrast, those with over 50% of breast density can
have over 2.3 times higher risk.7 High breast density is defined as having >75%
fibroglandular tissue and can increase breast cancer risk 4-5 times compared to lowdensity breasts.9
High-density breasts contain more structured collagen, favoring breast cancer
growth and localization.5 Furthermore, as seen in Figure 1-2, high-density breasts also
have higher levels of collagen-binding proteoglycans lumican, decorin, fibromodulin, and
biglycan. Lumican, for example, is an extracellular matrix protein that can induce breast
cancer initiation and progression through angiogenesis, epithelial cell growth, migration,
and invasion.5 The increased levels of structured collagen and lumican in the
extracellular matrix increase its stiffness, promoting cancer formation and proliferation.5
Moreover, dense breasts have been shown to have a pro-tumorigenic immune
microenvironment with increased macrophages, dendritic cells, T-cells,

B-cells, and

interleukin-6 (IL-6) levels. This pro-tumorigenic microenvironment can aid escape
immune regulation. Sadly, high breast density affects approximately 43% of women
ages 40-74 (50% in the U.S.) and accounts for 39% of premenopausal and 26% of
postmenopausal breast cancer.10, 11
Several factors can be associated with mammographic or breast density,
including inheritance, parity status and the number of births, race, ethnicity, diet, and
5

hormonal replacement therapy.12,

13

35-40% of these factors for breast density can be

considered modifiable and variable while 60-65% of these can be hereditary.13 For
example, breast density can decrease with age, especially after menopause. High body
mass index and larger breasts are also usually associated with low breast density.13 On
the other hand, later menarche can be associated with increased breast density.13
The tissue complexity associated with high breast density, aside from increasing
the risk of developing breast cancer, can also impede the ability of conventional
mammography to detect cancer by lowering its sensitivity, as will be described in the
next section.

Figure 1-2: Biological differences between low and high mammographic density. Figure
adapted with permission from reference 5.
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1.2.2

Breast cancer imaging

1.2.2.1 Conventional Mammography
As mentioned above, early detection of breast cancer can help improve patients'
prognosis and 5-year survival rate. Breast cancer screening has been shown to reduce
breast cancer mortality by 30-58%.14-17 The U.S. Preventive Services Task Force, a
panel of national experts in disease prevention and evidence-based medicine,
recommends screening for breast cancer biennially for women aged 50-74 years.18
Mammography is considered the gold standard for breast cancer screening. A
mammogram is a low dose x-ray image of the breast tissue. It has significant
advantages over other breast imaging techniques due to a combination of its high
sensitivity (77%–95%) and specificity (94%–97%), low cost, and tolerability.18, 19
Mammography fundamentally works similar to other x-ray imaging techniques. In
brief, x-rays are generated in an x-ray tube by directing electrons to an anode usually
made of molybdenum or rhodium.20 The incoming electrons release x-rays
(Bremsstrahlung) as they decelerate when in close contact with the anode.20 In addition,
characteristic x-rays can be generated following the interaction of an incoming electron
with an atom in the target, kicking out an electron and leaving a vacant electron shell.20
When another electron fills this vacancy, energy is released in the form of an x-ray
photon with a specific energy.20 Therefore, the x-ray energy spectrum comprises both
Bremsstrahlung and characteristic x-rays (Figure 1-3). Once the x-ray spectrum has
been generated, it is filtered using rhodium filters to reduce the low-energy components.
The x-ray is then focused on the subject where it can interact in two forms: photoelectric
effect or Compton scattering. The photoelectric effect occurs when an electron is ejected
from the innermost shell as a result of an x-ray photon with equal or higher energy than
7

the K-edge or binding energy of the electrons in the K-shell. When the x-ray energy is
above the K-edge of the element, the photoelectric effect results in a sudden increase in
x-ray attenuation which increases cubically with increasing atomic number (Z3, where Z
= atomic number). The K-edge energy is specific to each material and occurs just above
the binding energy of the K-shell electrons. Compton scattering, on the other hand,
results in scattered radiation due to the interaction of x-rays with free or loosely bound
valence shell electrons. These interactions increase with increased tissue density, thus,
facilitating the distinction between different tissues. Lastly, a detector records the x-ray
photons that have passed through the subject, followed by the generation of an image
which can be used for screening or diagnostic purposes.

8

Figure 1-3: Schematics of x-ray generation. a) Depiction of Bremsstrahlung radiation
generation. b) Depiction of characteristic radiation generation. c) Depicts a typical x-ray
emission spectrum showing Bremsstrahlung and characteristic radiation. Figure adapted
with permission from reference 21.
As previously discussed, breast tissue is composed of adipose and fibroglandular
tissue. Each of these tissues and tumors have different x-ray attenuation coefficients, as
shown in Figure 1-4, where at lower energies, these differences in attenuation are
larger.22

Thus, low x-ray tube voltages (25-40 kV) are used in mammography to

maximize the contrast and distinguish between the tissues. However, as observed in
9

Figure 1-4, the x-ray attenuation curves for the fibroglandular tissue and tumor are very
similar, thus giving rise to one of the main challenges with this technique in women with
dense breasts.

Figure 1-4: Linear attenuation coefficients of adipose tissue, fibroglandular tissue, and
breast tumor. Figure adapted with permission from reference 22.
Due to the similarity in attenuation between fibroglandular tissue and tumors, the
sensitivity for conventional mammography in women with dense breasts can decrease
from 87% to 30-50%, and the specificity also decreases from 96% to 90%.18,

23-25

As

shown in Figure 1-5 A2, the predominantly adipose tissue in the low mammographic
dense breast appears to be relatively translucent in the mammogram, whereas the
fibroglandular tissue in the breast with high mammographic density appears to be white
in the mammogram. Discerning between normal tissue and a breast lesion in highdensity breasts can be difficult as both appear white (Figure 1-5, panel B2). Therefore,
while mammography screening continues to be the commonly used breast cancer
10

screening method, the results in women with dense breasts can be inconclusive, could
generate false negatives, or false positives.

Figure 1-5: Schematic representation of mammography gland organization in breasts
with A1) low and high MD and B1) malignant lesions. Representative mammograms of
breasts with A2) low and high MD and B2) malignant breast lesions. MD:
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mammographic density; DCIS: ductal carcinoma in situ; IDC: invasive ductal carcinoma.
Figure was adapted with permission from reference 26.

Other imaging modalities have been used to address these limitations, including
breast MRI, breast ultrasound, and clinical breast exams. Breast MRI has been used as
the preferred imaging modality for patients with dense breasts. Breast MRI has higher
sensitivity (up to or close to 100%) than the other breast imaging techniques.27-31
However, breast MRI has a higher cost than mammography and is less widely
available.27 For patients who cannot undergo breast MRI, ultrasound can also be used.
Breast ultrasound, while it cannot be used alone as a breast cancer screening method,
can be beneficial when combined with mammography.7,

9

In addition to these imaging

modalities, other mammography techniques have been recently developed, including
breast tomosynthesis, which creates a 3-dimensional mammographic reconstruction of
the breast. However, while some improvement has been shown in women in BI-RADS
categories B & C, this technique has not been proven to address the limitations of
conventional mammography in women with highly dense breasts (category D in BIRADS).32, 33

1.2.2.2 Dual-energy mammography (DEM)
DEM, or contrast-enhanced mammography, is a newly developed mammography
technique recently approved by the Food and Drug Administration (FDA) for clinical use
to supplement conventional mammography for breast cancer screening, especially for
women with dense breasts.34 Like conventional mammography, DEM is of low cost (4
12

times lower than MRI), fast (7-10 min for DEM vs. 30-60 min for MRI), and has better
sensitivity and specificity than conventional mammography and breast ultrasound.34-36
DEM has a similar level of radiation exposure to that of a conventional mammogram (1.2
times the dose).36,

37

Moreover, DEM has a sensitivity comparable to that of contrast-

enhanced MRI (97%) with higher specificity (66% in DEM vs. 52% in contrast-enhanced
MRI).35, 38, 39
DEM uses conventional mammography and combines contrast agents with dualenergy image acquisition to better detect breast cancer regardless of breast density. The
contrast agent takes advantage of the comparatively high vascularization of cancer to be
at higher concentrations in breast tumors.40 Tumors require oxygen and nutrients to
support their growth.41, 42 As the tumor grows and these essential nutrients are limited, it
becomes hypoxic and releases vascular growth factors to promote neovasculature to
further increase its access to nutrients and grow.41,

42

DEM contrast materials take

advantage of this cancer hallmark to diffuse into this neovasculature to highlight breast
tumors.
In a typical DEM scan, a contrast material is administered intravenously.
Approximately 2 minutes after contrast administration, the breasts are compressed, and
a low-energy image is acquired, as is done in conventional mammography (Figure 16A). The low-energy image is acquired at an energy below the K-edge of the contrast
material. Next, a high-energy image is acquired at an x-ray energy above the K-edge of
the contrast material to reveal the contrast uptake (Figure 1-6B). The low energy and
high energy (contrast-enhanced) images are subject to a weighted logarithmic
subtraction described in the equation below. The resulting image highlights the contrast
agent accumulation in the tumor (Figure 1-6C).
13

SI = signal intensity, DE = dual-energy, HE = high energy, LE = low energy, and w =
weighing factor

Figure 1-6: Example of the images acquired with dual-energy mammography. A typical
dual-energy mammogram consists of acquiring a low energy image (A) followed by a
high energy image (B) which are used to generate a subtraction image (C). Figure was
adapted with permission from reference 43.

In addition to being used as a diagnostic imaging tool, several studies have
evaluated the use of DEM in the preoperative staging of women newly diagnosed with
breast cancer. These studies have shown that DEM can accurately assess the index
tumor size, detect additional sites of disease with similar or possibly slightly inferior
14

accuracy, and detect other lesions with superior positive predictive value compared to
MRI.44 DEM has also been studied as a tool for monitoring response to neoadjuvant
chemotherapy where early data has shown DEM to be promising in predicting response
to therapy.44
Aside from all the benefits and clinical relevance mentioned above, DEM uses
standard mammography equipment, if updated to include a copper filter and software
with dual-energy capabilities.37 Most importantly, DEM has been shown to improve
breast cancer detection in women with dense breasts.45,

46

Thus, DEM is a promising

supplemental imaging technique for breast cancer screening regardless of breast
density.

1.2.3

X-ray contrast agents

1.2.3.1 Introduction
X-ray imaging is composed of several techniques which use x-rays to generate
images to discern different tissues and organs. X-ray imaging techniques include
conventional x-ray radiography, CT, and fluoroscopy. Among these, CT has been more
widely used and has become one of the primary imaging modalities used for the imaging
and detection of various diseases. CT is non-invasive, has a high resolution, and has
deep tissue penetration. However, as described with conventional mammography,
differentiating between normal and pathologic tissue in x-ray imaging without a contrast
agent can be challenging. X-ray contrast agents have been designed to enhance the
visibility of different soft tissues within the body in x-ray imaging techniques. Moreover,
recent advances in the development of x-ray contrast agents have resulted in agents
with multiple capabilities, including the ability to be targeted to specific tissues. In the
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following sections, I will discuss the most common types of x-ray contrast agents,
including iodinated contrast agents and the use of NPs as x-ray contrast agents.

1.2.3.2 Iodinated contrast agents
Iodinated, small molecule contrast agents are most commonly used for clinical xray imaging. Iodine (Z = 53) has a high mass x-ray absorption coefﬁcient (1.94 cm2 g-1 at
100 keV), allowing for the distinction between the contrast agent and soft tissue.47
Iodine-based contrast agents were initially developed as ionic, mono-iodinated
molecules, such as sodium iodide. Their structure has since evolved to nonionic, triiodinated benzoic acid derivatives such as iohexol.48 The current formulations provide
excellent water solubility, improved biological tolerance, and low osmolality. These
properties have supported their wide use in several x-ray imaging modalities, including
CT and DEM.
In their non-ionic, low-osmolarity form, iodinated contrast agents are used in
DEM. Iodine’s K-edge energy (33.2 kV) is within the x-ray energy ranges used in DEM.
In the high-energy images acquired during a typical DEM scan, obtained at energies (4449 kV) above the contrast material’s K-edge, a distinct difference in the attenuation
between the breast tissue and iodinated contrast material can be observed. Therefore,
as discussed previously, the accumulation of the iodinated contrast agent in the tumor’s
neovascularity can help detect breast tumors with better specificity and selectivity than
conventional mammography.34-36 While iodinated contrast agents have helped make
significant progress in the use of DEM, they possess various disadvantages.
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Despite the efforts made to optimize the physicochemical properties of iodinated
contrast agents, further improvement is still needed given their very short blood
circulation times and limited contrast due to low payloads.49 They are also nonspecific,
which leads to random vascular permeation and very low tumor accumulation. Moreover,
they can induce nephrotoxicity in those with renal disease, and they are known to cause
adverse reactions in some patients.50-53 To overcome these limitations, a range of
elements and various formulations have been proposed as potential alternative X-ray
contrast agents.

1.2.3.3 Nanoparticles as x-ray contrast agents
Nanoparticles (NPs) are particles of matter with at least one dimension between
1 to 100 nm in diameter.54 NPs have unique physicochemical properties different from
bulk, and some of their properties can be tuned based on the NP shape and or size. NPs
have been widely used as x-ray contrast agents to improve the limitations presented by
iodinated agents. NPs offer 1) high surface-to-volume ratio, 2) surface functionalization
and targetability to different tissues and organs, 3) high plasma circulation times, 4) high
payloads, and 5) can be developed in a variety of materials, including inorganic (e.g.,
metals) and organic (e.g., liposomes, micelles, polymers) materials, or a combination of
these.55 Moreover, NPs can be designed to be used as multimodal contrast agents for
their application in multiple imaging techniques. Figure 1-7 presents a schematic
illustrating the properties that can be incorporated into the design of NPs. In x-ray
imaging, the most common nanoparticle-based contrast agents are metal and lipidbased.20
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Figure 1-7: Schematic representing some of the nanoparticles' diverse properties and
compositions and potential surface modifications. Figure adapted with permission from
reference 56.

Inorganic NPs for x-ray imaging are made of metals with high attenuation
coefficients and K-edges, both of which increase with the atomic number in the periodic
table. Therefore, heavy metal-based (e.g., lanthanides, tantalum, bismuth, and gold) NP
contrast agents have been preferred in x-ray imaging.57-62 Among the metal-based x-ray
contrast agents, gold (Z= 79) NPs are the most extensively studied due to their high
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density, CT-relevant K-edge (80.7 keV), biocompatibility, and the broad availability of
syntheses leading to tunable size, shape, and other properties.63-66 Moreover, gold has a
higher x-ray absorption than iodine at high (100 keV) and low energies (< 30 keV),
making gold NPs useful for not only clinical CT (energies ranging from 80-140 keV) but
also fluoroscopy (75-125 keV energy range), and mammography (<30 keV energy) .67, 68
On the other hand, lipid-based NPs for x-ray imaging are generally in the form of
micelles, emulsions, or liposomes. Lipid-based NPs, loaded with iodine-based contrast
agents, were the first NPs reported for CT imaging and have attracted much attention
since then.69 Lipid-based NPs are attractive due to their ease of synthesis, ability to be
loaded with different multifunctional substances, and biocompatibility.69 Figure 1-8
summarizes the different types of lipid-based NPs and their lipid arrangement.
Liposomes are aggregates of lipids forming a bilayer enclosing an aqueous core. These
became the first nanomedicines in FDA clinical trials.70 An oil-in-water emulsion is a lipid
coating encapsulating a droplet of a hydrophobic substance. On the other hand, micelles
are lipid monolayers with a hydrophobic core and hydrophilic surface. Micelles are
formed when the lipid concentration rises above its critical micellar concentration. Due
to the amphiphilicity of the lipid molecules, lipid-based NPs can encapsulate both
hydrophobic and hydrophilic substances, including both drugs and/or contrast materials,
depending on the lipid structure and arrangement.69, 71 These lipid-based NPs have been
loaded with both iodinated materials as well as inorganic NPs to be used as x-ray
contrast agents.72-76 Furthermore, lipid-based NPs have been developed to show a
slower release of the load, longer blood circulation times, and have been targeted to
different tissues. Many of these lipid-based formulations, based on their design and
properties, have resulted in large-sized (> 5 nm) NPs.
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Figure 1-8: Lipid-based nanoparticles.A) Schematic representation of amphiphilic lipids.
B) Schematic representation of lipid-based nanoparticles. Figure was adapted with
permission from reference 77.

Large NPs (> 5 nm), or blood pool agents, remain in circulation for an extended
time due to their lack of transport across the kidneys' glomerular filtration barrier,
providing contrast for a longer period and an opportunity to enter disease sites.78 The
angiogenesis cancer hallmark, previously described, creates a “leaky” vasculature with
large gaps (approx. 1.5 µm) between endothelial cells in the tumor blood vessels.79, 80
Blood pool agents can extravasate the tumor’s leaky vasculature and passively
accumulate in the tumor tissue through the enhanced permeability and retention (EPR)
effect, as represented in Figure 1-9C. While leaky vasculature can be seen in other
diseases, this effect does not occur in normal tissue. Thus, the EPR effect has been
20

advantageous in tumor/disease imaging and drug delivery. These advantages have
expanded the use of blood pool agents as x-ray contrast agents.
Aside from size, other factors can improve the circulation time of NPs. For
example, the NP surface can be modified with stealth molecules such as hydrophilic
polymers ( e.g., polyethylene glycol (PEG)) or bio-stealth materials (e.g., cell-membrane
coating and protein functionalization) to increase their size and prevent NP aggregation
and opsonization.81-86 The mononuclear phagocyte system (MPS), which consists of
dendritic cells, blood monocytes, granulocytes, and macrophages in the liver, spleen,
and lymph nodes, is responsible for rapidly clearing NPs and other foreign materials
from the blood.81 Prevention of opsonization, or the process by which phagocytes can
take up NPs for elimination, increases the NPs' circulation time.82 PEGylation, due to its
neutral surface charge, can also prevent the adsorption of serum proteins in the NP
surface, which can form a protein corona.82,

87, 88

This protein corona facilitates NP

uptake by cells, similar to the MPS cell uptake, and can cause NP aggregation.88, 89 NP
aggregation can affect their circulation time regardless of cellular uptake by the MPS or
other cells. Large aggregated NPs can become lodged and accumulate in the pulmonary
capillary beds, eliminating them from circulation.81,

90

While PEGylation has been the

primary NP surface modification used in literature, other polymers such as zwitterionic
polymers or bio-stealths can have a similar effect.86, 88, 91-94 Thus, surface modifications
have become an important aspect in x-ray NPs used as contrast agents.95-97
Although incorporating stealth molecules into the NP design has improved the
circulation time of NP contrast agents, these still tend to eventually accumulate in MPS
organs such as the liver and spleen. Kupffer cells in the liver and macrophages in the
spleen are the main cells responsible for MPS NP uptake, as represented in Figure 121

9A. This accumulation in MPS organs is primarily due to the NPs’ large size (> 5 nm), as
these are unable to cross the glomerular barrier for renal elimination.78 Uptake by MPS
organs results in a very slow NP elimination process which can take months to years to
complete.98,

99

Thus, long-circulating NPs can represent a toxicity challenge, and

therefore, strategies to optimize the NP clearance while retaining their long circulation
are of great interest in the field.
Renally excretable NPs (<5 nm) are designed to cross the glomerular filtration
barrier and achieve urinary clearance, as represented in Figure 1-9B. This urinary
clearance is carried out in the nephron, the primary functional unit of the kidney.100 The
nephron includes the renal corpuscle where the glomerulus, a network of capillaries
enclosed in the Bowman’s capsule, is located. The glomerulus filters the blood that
reaches the kidneys through the renal artery. The glomerular filtration barrier comprises
three layers with distinctive pore size and surface charges: the fenestrated endothelial
cells lining the capillaries, the glomerular basement membrane (GBM), and the podocyte
with their “slit diaphragms”.101 As described by Hsu et al., a monolayer of glycocalyxcoated endothelial cells with fenestrations of 70–90 nm in diameter lines the glomerular
capillaries. These endothelial cells are supported by the glomerular basement
membrane (GBM) that has a net polyanionic charge and contains 2–8 nm pores. The
distal layer of the GBM is composed of podocytes with foot processes that form narrow
and uniform filtration slits of 4–11 nm in width. The surface of this layer is also covered
by negatively charged glycoproteins.20, 101 Thus, to cross the glomerular filtration barrier,
NPs should be designed to meet these size and charge requirements. A hydrodynamic
size threshold of 5.5 nm has been established for ultra-small NPs and 40 kDa for
molecules and proteins to be able to cross the filtration barrier.78 Recent studies have
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shown that NPs with low molecular weight zwitterionic or neutral coatings can cross the
glomerular filtration barrier more rapidly and efficiently.78, 94, 102, 103 While size and surface
coatings have been reported as the main determinants for NP renal clearance, other
factors, such as the core composition, can also impact the renal clearance of NPs.100, 104107

The renal clearance of NPs decreases with increased material density.104 NPs able

to cross the glomerular filtration barrier can be rapidly eliminated from the body
minimizing the uptake in MPS tissues. Therefore, renally excretable NPs can avoid
potential safety concerns associated with the MPS’ slow elimination process.

Figure 1-9: Schematic representation of the size-dependent biodistribution of bloodcirculating nanoparticles. Cellular barriers in A) liver, B) kidneys, C) tumor, and D) cell
membranes. A) Macrophages can take up large nanoparticles in the liver. B)
Nanoparticles <5.5 nm can cross the kidney’s glomerular filtration threshold and be
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excreted in the urine. C) Nanoparticles in the 30-200 nm range can extravasate the
tumor’s leaky vasculature. D) Nanoparticles are mostly internalized through endocytosis.
Key: (i) endothelial cell; (ii) Kupffer cell; (iii) hepatocyte; (iv) glomerular basement
membrane; (v) tumor cell. Figure was adapted with permission from reference 94.

1.2.4

DEM contrast agents

1.2.4.1 Materials with potential for use as DEM contrast agents
Given the advantages of NP-based contrast agents compared to iodine-based
agents, an interest in developing NP-based contrast agents specifically for DEM has
emerged. To identify materials specifically optimized for DEM contrast agents,
Karunamuni and Maidment quantitatively compared the DEM contrast of every material
in the range of Z= 1 to 80.108 The study revealed that elements with Z= 42 to 63 had the
maximum contrast-to-noise ratio (CNR) (partially summarized in Table 1-1). Silver (Z =
47) was among the elements with a high contrast-to-noise ratio. Silver NPs represent
one of the largest and fast-growing areas in nanotechnology, with numerous syntheses
available for their development.109, 110 Yet, until recently, of the high-contrast generating
elements, only iodine had been investigated for its use as a DEM contrast agent.
Karunamuni et al. tested the potential of silver as an alternative for iodine-based contrast
agents in DEM, where they found silver had a 40-43% higher signal difference-to-noise
ratio than iodine.111 With this in mind, Karunamuni et al. tested the use of silver NPs as
DEM contrast agents.112 This group developed silica-encapsulated silver NPs coated
with PEG with a hydrodynamic diameter of 115 nm and demonstrated their high DEM
contrast. While these studies served as an initial platform for developing other silverbased DEM contrast agents, further improvements in the design of NPs were needed to
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promote better biocompatibility, excretability, and higher silver ratio for optimal
contrast.113

Table 1-1: Potential materials to be used as DEM contrast agents. Table adapted with
permission from reference 108.

Material

Z

K-edge

Maximum CNR

Molybdenum (Mo)

42

20.0

40.3

Rhodium (Rh)

45

23.2

39.0

Palladium (Pd)

46

24.4

40.4

Silver (Ag)

47

25.5

42.6

Tin (Sn)

50

29.2

44.1

Tellurium (Te)

52

31.8

41.9

Iodine (I)

53

33.2

42.6

Barium (Ba)

56

37.4

44.1

1.2.4.2 Silver chalcogenides
Our group has sought to develop NPs to be used specifically as DEM contrast
agents based on the previously described investigations. Aside from high contrast in
DEM, these NPs should have colloidal stability and be biocompatible in vitro and in vivo.
Pure silver NPs, while providing high contrast in DEM, are toxic due, in part, to the
release of silver ions.114-116 Some of the mechanisms reported related to silver NP
toxicity include induction of apoptosis, DNA damage, increased mitochondrial membrane
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permeability, and accumulation of reactive oxygen species.117-119 In our efforts to develop
NP DEM contrast agents with high contrast and biocompatibility, we looked into other
elements that produce high contrast and can be combined with silver to synthesize NPs.
Among them, tellurium (Z = 52) was of interest. When combined with silver, tellurium can
form silver telluride (Ag2Te) NPs. Ag2Te NPs are composed of two high contrast
generating materials for DEM and have excellent biocompatibility due to their extremely
low solubility product (Ksp = 2.0 x 10-72) and, thus, a significantly lower release of toxic
metal ions. This low solubility product is characteristic of silver chalcogenides (Ag2X, X =
S, Se, or Te).
Ag2X NPs are comprised of silver sulfide (Ag2S), silver selenide (Ag2Se), Ag2Te,
and combinations thereof. Like other chalcogenide-containing (elements in the sixteenth
group of the periodic table and especially sulfur, selenium, and tellurium) materials,
these NPs exhibit characteristic optical properties that are well-suited for biomedical
applications. Some of their biomedical applications include near-infrared fluorescence
imaging,

photoacoustic

imaging,

photothermal

ablation,

and

some

types

of

biosensing.120-124 Moreover, Ag2X, being silver-based NPs, can also be used as x-ray
contrast agents. Our group has investigated Ag2S NPs for X-ray imaging in two recent
studies.102, 125 In the first study, Hsu et al. developed an all-in-one multimodal NP-based
contrast agent to detect breast cancer using near-infrared fluorescence, MRI, CT, and
DEM. The multimodal NPs were formed by co-encapsulating a near-infrared fluorophore,
Ag2S NPs, and iron oxide NPs in PEGylated micelles. These NPs produced strong
contrast in the studied imaging modalities. In DEM specifically, the NPs generated
strong contrast in vivo after being administered to breast cancer tumor-bearing mice.
Moreover, these all-in-one NPs showed negligible cytotoxicity, confirming the excellent
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biocompatibility shown in Ag2X NPs. In a second study, Hsu et al. developed 3 nm-sized
Ag2S NPs as renally excretable NP contrast agents for CT and DEM.102 These NPs
showed high DEM contrast, comparable to that of pure silver while maintaining excellent
biocompatibility due to their minimal release of toxic silver ions. Moreover, their small
size and coating allowed for their fast renal excretion (85% of injected dose in 24 hours),
further highlighting their potential to be used as safe and effective DEM contrast agents.
Additional to the work described above, we hypothesize that the incorporation of
tellurium, in the form of Ag2Te, will yield a further improved DEM contrast agent. While
the contrast produced by S and Se is negligible in DEM, the K-edge of tellurium (32 keV)
also falls within the diagnostic X-ray energy window; therefore, Ag2Te NPs should
generate high X-ray contrast due to the combination of the two contrast generating
elements while maintaining the biocompatibility characteristic of Ag2X NPs.126 Moreover,
by functionalizing the Ag2X NPs with different targeting moieties, drug delivery and
imaging of specific tissues or cells can be achieved. In addition to these important
properties, Ag2X NPs have low material ($0.73 per gram of Ag) and fabrication costs,
especially when synthesized under aqueous conditions, which can be an attractive
feature for future large-scale production.127

1.2.4.3 Transition metal dichalcogenides
Another element of interest for developing DEM contrast agents with high
contrast and biocompatibility is molybdenum. In the previously described study by
Karunamuni et al., molybdenum (Z = 40), with a K-edge energy of 20 kV, yielded
comparable contrast to iodine (Table 1-1).108 Yet, its toxicity to humans is extremely
low.128,

129

Molybdenum is an essential trace element that binds to molybdopterin
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cofactors to serve a role in the following enzymes in the human body: sulfite oxidase,
xanthine oxidase, aldehyde oxidase, and mitochondrial amidoxime-reducing component
(mARC).128 In these enzymes, molybdenum catalyzes oxygen transfer reactions from or
to substrates using water as an oxygen donor or acceptor. Molybdenum can also be
found in our diet. Beans are the richest source of the element, but it can also be found
in grains, vegetables, and dairy products.128 In addition to its important role in the human
body, molybdenum can be combined with sulfur to create molybdenum disulfide (MoS2)
NPs. MoS2 NPs are transition metal dichalcogenides (TMDs) and have unique and
attractive properties for their biomedical use.
TMDs are semiconductor materials in the form of MX2, where M is a transition
metal (such as Mo, Ti, or W) and X is a chalcogen (S, Se, and Te). They are considered
graphene analogs and, as such, have received significant attention. TMDs are structured
as monolayers of form X – M – X, where metal atoms are hexagonally packed between
two planes of chalcogens.130,

131

TMDs have unique electrical, mechanical, and optical

properties, in addition to their low toxicity, which makes them attractive in many
applications.130,

132-134

When synthesized as quantum dots, TMDs have the added

advantage of a large surface area that improves their catalytic activity and sizecontrolled optical properties, making them more attractive for bioimaging applications.135
These different properties make TMDs suitable for photothermal and photodynamic
therapy, drug/gene delivery, bioimaging, and as biosensors.135-138
Despite their different uses in the biomedical field, only recently have TMDs been
explored as x-ray contrast agents. In a study conducted by Yong et al. in 2014, BSAcoated WS2 nanosheets developed for photodynamic and photothermal therapy of
cancer cells were studied as x-ray contrast agents showing their strong x-ray
attenuation, in agreement with other studies.139-141 In a study conducted in 2014 by Yin et
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al., chitosan-coated MoS2 nanosheets, developed as photothermal triggered drug
delivery vehicles for cancer therapy, were also tested as x-ray contrast agents.142 Here,
the MoS2 nanosheets showed slightly higher x-ray attenuation than Iopromide, a
commercially available CT contrast agent.142 More recently, MoS2 quantum dots were
explored as x-ray contrast agents in the work presented by Wang et. al..143 In this study,
polyaniline MoS2 quantum dots were synthesized as multimodal contrast agents for
photoacoustic and CT imaging and as radiotherapy/photothermal therapy agents. The
MoS2 were biocompatible at the studied conditions and showed CT attenuation.
However, the concentrations used in this study were low, and no data on the
biodistribution or long-term safety of the quantum dots was provided. These limited
studies on the x-ray contrast produced by TMDs and, more specifically, MoS2 NPs have
given our group the basis to explore the use of MoS2 NP as x-ray contrast agents in both
DEM and CT.

1.3 Preface to dissertation
DEM is a newly developed breast imaging technique capable of detecting breast
cancer regardless of breast density.34,

45, 46

DEM has similar sensitivity and higher

specificity than breast MRI.35, 38, 39 It also has low cost, is fast, and can utilize the same
equipment used in conventional mammography.34 DEM requires the administration of a
contrast agent, which defuses into the tumor site for better detection. For this, iodinebased contrast agents are currently used in the clinic. However, these do not possess
optimal contrast for DEM, have short circulation times, can cause an allergic reaction
and contrast-induced nephropathy in some patients, and can have non-specific
localization.49-53 NPs, on the other hand, can address some of these described
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shortcomings. Thus, a need for DEM-specific NP-based contrast agents currently exists.
Karunamuni et al. tested 80 materials and generated a list of materials with high DEM
contrast.108 Among these materials, silver has been shown to have substantially higher
contrast than iodine. However, elemental silver NPs are toxic due to the release of silver
ions that can increase the levels of reactive oxygen species in a cell, causing oxidative
stress and cell damage.117-119 Our group has explored different silver material
combinations such as gold-silver alloys to minimize the potential toxicity associated with
silver NPs while maintaining their DEM contrast.113 Another material combination
explored in our lab has been Ag2X, in the form of Ag2S.102, 125, 144 Ag2X have the added
benefits of having a low solubility product which leads to an extremely slow release of
silver ions and thus improving their biocompatibility while maintaining higher contrast in
DEM than iodine-based contrast agents.127
Based on these initial studies, I have identified several modifications leading to
improvements in contrast generation, biocompatibility, clearance, and cost for DEMspecific contrast agents. In my first project, I propose using Ag2Te NPs as DEM contrast
agents. Ag2Te NPs are made of two high contrast generating materials for DEM, as
described by Karunamuni et al.,108 resulting in improved NP contrast in DEM. In addition,
Ag2Te has a lower solubility product than Ag2S, suggesting higher biocompatibility in the
samples.127 Additionally, I propose using CT-relevant NP doses (> 100 mg/kg) in the
experiments. While relevant to CT, these doses are much higher than those required by
other imaging or therapeutic applications. The results of these experiments will further
highlight the biocompatibility of the NPs and could potentially lead to further exploration
of the material in other biomedical applications. Moreover, Ag2Te NPs are of low cost.
The current prices for silver and tellurium are $0.78 and $0.07 per gram, respectively.
Therefore, a dose of Ag2Te NP for a woman with an average weight would cost about
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$15.77. This cost is much lower than gold NP x-ray contrast agents ($1,144.55). In my
second project, I propose the synthesis of renally excretable Ag2Te NPs. Aside from all
the advantages of Ag2Te NPs described above, renally excretable Ag2Te NPs will be
rapidly eliminated from the body. This reduces the potential long-term toxicity associated
with NP accumulation in the MPS organs which can reside in the body for months to
years. This long-term retention can hinder their clinical translation.78 Therefore, renally
excretable NPs could have higher contrast, good biocompatibility, and be rapidly
eliminated from the body, suggesting a clinically translatable contrast agent specifically
designed for DEM. My third proposed project will study the use of MoS2 NPs as DEM
contrast agents. Molybdenum is listed as a material with contrast generation in DEM.108
MoS2 NPs have great versatility in their biomedical applications, have been shown to be
biocompatible, and are of low cost. At the current price of $0.04/g of Mo and $0.2/g of S,
a dose of MoS2 as DEM contrasts agents for a woman with average weight will cost
$8.50. MoS2 NPs have only recently been explored as x-ray contrast agents and to the
best of our knowledge, it has not been explored as DEM specific contrast agent.
This dissertation describes the design and synthesis of Ag2Te NPs as DEM and
CT contrast agents as well as renally excretable agents. Furthermore, it describes the
design and synthesis of MoS2 NPs as DEM contrast agents. To the best of our
knowledge, limited studies have been reported in the use of these materials as x-ray
contrast agents and have not been explored as DEM-specific contrast agents. The
subsequent chapters will cover the following topics and objectives:
Chapter 2: Develop silver telluride nanoparticles as proof-of-concept DEM and
CT contrast agents for breast cancer screening.
Chapter 3: Develop renally excretable silver telluride nanoparticles as safe x-ray
contrast agents with translational potential.
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Chapter 4: Develop molybdenum disulfide nanoparticles with different coatings
and evaluate their potential as renally excretable x-ray contrast agents.
Chapter 5: Summarize the major discussion points and address this dissertation
work's limitations and future directions.
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Chapter 2: Silver telluride nanoparticles as biocompatible and
enhanced contrast agents for x-ray imaging: an in vivo breast cancer
screening study

This chapter was adapted with permission from Nanoscale, 2021, 13, 163-174.

2.1 Abstract
Silver sulfide nanoparticles (Ag2S NPs) have gained considerable interest in the
biomedical field due to their photothermal ablation enhancement, near-infrared
fluorescence properties, low toxicity levels, and multi-imaging capabilities. Silver telluride
nanoparticles (Ag2Te NPs) have similar properties to Ag2S NPs, should also be stable
due to an extremely low solubility product, and should generate greater x-ray contrast
since tellurium is significantly more attenuating than sulfur at diagnostic x-ray energies.
Despite these attractive properties, Ag2Te NPs have only been studied in vivo once and
at a low dose (2 mg Ag kg-1). Herein, for the first time, Ag2Te NPs’ properties and their
application in the biomedical field were studied in vivo in the setting requiring the highest
nanoparticle doses of all biomedical applications, i.e., x-ray imaging. Ag2Te NPs were
shown to be stable, biocompatible (no acute toxicity observed in the cell lines studied or
in vivo), and generated higher contrast, compared to controls, in the two x-ray imaging
techniques studied: computed tomography (CT) and dual-energy mammography (DEM).
In summary, this is the first study where Ag2Te NPs were explored in vivo at a high dose.
Our findings suggest that Ag2Te NPs provide strong x-ray contrast while exhibiting
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excellent biocompatibility. These results highlight the potential use of Ag2Te NPs in the
biomedical field and as x-ray contrast agents for breast cancer screening.

2.2 Introduction
Nanomaterials are known for their unique physical and chemical properties,
including their exceptional optical characteristics, ability to be engineered to obtain
desired properties through the modification of their surface, size, and composition, as
well as their tunable pharmacokinetics. These unique characteristics have led to the
exploration of nanomaterials in biomedical applications,1 such as fluorescence imaging
and sensing probes,2 drug delivery vehicles,3 theranostic agents,4 and contrast agents
for several medical imaging techniques,5-8 and have been key to innovation and
progression in the field. Several groups, including ours, have recently studied silver
chalcogenides such as silver sulfide (Ag2S NP) and silver selenide nanoparticles (Ag2Se
NP) in the biomedical field due to their photothermal ablation enhancement, nearinfrared fluorescence properties, low toxicity levels, and x-ray contrast generation.9-14
In addition to Ag2S and Ag2Se, the silver chalcogenide group also includes silver
telluride (Ag2Te). Ag2Te has an extremely low solubility product (Ksp= 2 x 10-72),15 much
lower than those of Ag2S and Ag2Se (6 × 10−50 and 3 x 10-65, respectively), and could
consequently also have excellent stability and biocompatibility16, 17. Moreover, tellurium
generates similar x-ray attenuation to silver, whereas the attenuation of sulfur and
selenium is negligible at diagnostic energies, therefore, the x-ray attenuation of Ag2Te
should be substantially higher than for Ag2S and Ag2Se.18 However, despite their
outstanding properties, Ag2Te NPs have been rarely explored in biomedical applications.
Ag2Te NPs have been explored as surface-enhanced Raman sensors, and their NIR-II
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imaging properties have been characterized.19, 20 However, only one other study to date
has explored the biomedical application of Ag2Te NPs in vivo, and at a low Ag2Te NP
dose.21
In this study, we propose taking advantage of the attractive properties of Ag2Te
NP to further explore their application in the biomedical field. We, therefore, tested
Ag2Te NPs in the setting that requires the highest nanoparticle doses of all biomedical
applications, i.e., x-ray imaging.22 We hypothesized that Ag2Te NPs can be excellent
contrast agents for two main x-ray imaging modalities: computed tomography (CT) and
dual-energy mammography (DEM). CT is the most widely used x-ray imaging technique
for whole-body imaging, while DEM is a newly developed multi-energy mammography
technology approved for breast cancer screening. Currently, both x-ray imaging
modalities rely on iodine-based contrast agents, which have been linked with contrastinduced nephropathy and allergic reactions.23 We hypothesize that Ag2Te NPs will meet
the needs of both x-ray imaging techniques, with higher contrast than Ag2S NPs due to
the presence of tellurium, while exhibiting excellent biocompatibility. In addition to silver
chalcogenides, other metal nanoparticles, including gold (Au) and Bismuth (Bi) have
been widely used in x-ray imaging, owning their high K-edge and x-ray attenuation
coefficient and their good biocompatibility.

24,5

However, the K-edge of these materials

are not suitable for DEM x-ray imaging for breast cancer screening, where Ag2Te
exhibits high contrast.18 In addition, silver chalcogenides are of significantly lower cost
than Au nanoparticles (i.e. $63/g Au vs $0.89/g Ag, and thus could be more accessible
to patients.
In this study, Ag2Te NPs were characterized using transmission electron
microscopy (TEM), dynamic light scattering (DLS), UV-vis spectroscopy, energy
dispersive x-ray spectroscopy (EDX), x-ray powder diffraction (XRD) as well as
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inductively coupled plasma optical emission spectroscopy (ICP-OES). We tested the
biocompatibility of the nanoparticles through a series of experiments both, in vitro,
through cell viability in different cell lines, and in vivo, through histology analysis.
Moreover, their ability to be used as x-ray contrast agents was explored in an in vitro
setting using different x-ray imaging modality phantoms, as well as in vivo through CT
imaging of breast cancer tumor-bearing mice. Furthermore, the biodistribution of these
nanoparticles in mice was also analyzed.

2.3 Materials and Methods
2.3.1 Materials
Silver nitrate (AgNO3), sodium borohydride (NaBH4), and sodium citrate
(Na3C6H5O7) were purchased from Sigma-Aldrich (St. Louis, MO). Sodium tellurite
(Na2TeO3) was purchased from Alfa Aesar (Haverhill, MA). Hydrazine (N2H4) 80% and
nitric acid (HNO3) were purchased from Acros Organics (Thermo Fisher Scientific, NJ)
and Fisher Chemical (Thermo Fisher, Waltham, MA), respectively. Monofunctional PEG
thiol (mPEG-SH) 5K was purchased from Creative PEGworks (Chapel Hill, NC). Milli-Q
deionized water (18.2 M.cm) was used throughout the experiments.

2.3.2 Nanoparticle Synthesis
2.3.2.1 Silver telluride nanoparticles (mPEG-SH 5K coated)
The synthesis protocol of silver telluride nanoparticles (Ag2Te NPs) was adapted
from a previous report.20 In brief, a 9 mL aqueous solution containing 5 mM of sodium
tellurite, 10 mM of silver nitrate, and 30 mM of mPEG-SH 5K was prepared. 1 mL of
hydrazine was quickly added to the previous solution. The mixture was then heated to
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90 C for 30 minutes under constant magnetic stirring. After the reaction was completed,
the product was washed thrice, with DI water, by centrifugation using 10 kDa
ultrafiltration molecular weight cut-off tubes (MWCO) at 4000 rpm. Following the third
wash, the nanoparticles were dispersed in DPBS and then washed by centrifugation at
the above-mentioned speed and using the same size MWCO tubes. The nanoparticles
were then concentrated to a final volume of 1 mL and filtered through a 0.22 µm filter.
The filtered nanoparticles were then stored at 4 °C for further use.

2.3.2.2 11-MUA coated silver telluride nanoparticles
The protocol used to synthesize 11-mercaptoundecanoic acid (11-MUA) coated
Ag2Te NPs was similar to that of PEG-SH coated NPs. In brief, 1 mL of hydrazine
hydrate was added to a 9mL aqueous solution containing 30mM of11-MUA, 5mM of
Na2TeO3, and 10mM of AgNO3. The reaction was allowed to proceed for 30 minutes in
an oil bath at 90C under magnetic stirring. The solution was placed on ice upon reaction
completion, followed by three washes with DI water using 10kDa ultrafiltration MWCO
tubes at 4000 rpm.

2.3.2.3 Silver nanoparticles
Silver nanoparticles (Ag NPs) were prepared as described in our previous work.25
In brief, 1.25 mL of 0.1 M sodium citrate were added to 500 mL of DI water, followed by
the addition of 1.25 mL of 0.1 M silver nitrate and 5 mL of 0.1 M sodium borohydride.
Next, 5 mL of 12.5 mg/mL mPEG-SH-5K were added to the reaction, which was left to
stir overnight. The resulting particles were purified thrice with DI water and concentrated
by centrifugation using 10 kDa MWCO tubes at 4000 rpm. Following the third wash, the
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nanoparticles were dispersed in DPBS and then washed by centrifugation at the abovementioned speed using the same size MWCO tubes. The nanoparticles were then
concentrated to a final volume of 1 mL and filtered through a 0.22 µm filter. The filtered
nanoparticles were then stored at 4 °C for further use.

2.3.2.4 Silver sulfide nanoparticles
Silver sulfide nanoparticles (Ag2S NPs) were prepared by mixing 0.375 mmoles
of AgNO3 and 0.012 mmoles of mPEG-SH 5K in 75 mL of DI water, followed by the rapid
addition of 0.38 mmoles of Na2S in 25 mL of DI water at ambient conditions. The
reaction was allowed to stir overnight at room temperature. The resulting particles were
purified three times with DI water and concentrated by centrifugation using 10 kDa
MWCO tubes at 4000 rpm. Following the third wash, the nanoparticles were dispersed in
DPBS and then washed by centrifugation at the above-mentioned speed using the same
size MWCO tubes. The nanoparticles were then concentrated to a final volume of 1 mL
and filtered through a 0.22 µm filter. The filtered nanoparticles were then stored at 4 °C
for further use.

2.3.3 Nanoparticle Characterization
2.3.3.1 Dynamic light scattering and zeta potential
The nanoparticles' hydrodynamic diameter and zeta potential were measured
using a Zetasizer (Nano-ZS 90, Malvern instrument, Malvern, UK). The number mean
was reported for the hydrodynamic diameter. All measurements were performed at 25
°C.
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2.3.3.2 Transmission electron microscopy
Nanoparticle core size was measured as described previously.9,

26

JEOL 1010

and Tecnai T12 electron microscopes were used with an acceleration voltage of 80 and
100 kV, respectively. 10 µL of the sample were placed onto Formvar carbon-coated
copper grids with 200 mesh (Electron Microscopy Sciences, Hatfield, PA) and allowed to
dry before imaging. ImageJ (National Institutes of Health, Bethesda, MD) was used to
measure the core diameter of individual nanoparticles.

2.3.3.3 UV/visible absorption spectroscopy
UV/visible spectra of silver telluride nanoparticles were recorded using a
Genesys 150 UV/visible spectrophotometer (Thermo Scientific, USA). In brief, 5 μl of the
nanoparticle stock were diluted with 995 µl of DI water.

2.3.3.4 Fourier transform infrared (FT-IR) Spectroscopy
Samples were prepared by diluting 5µL of the solutions of interest in 100 mg of
potassium bromide. The samples were then dried in an oven, compacted into pellets,
and analyzed using JASCO FT/IR 480 Plus.

2.3.3.5 Silver telluride nanoparticle stability study
Silver telluride nanoparticle solutions with a 0.5 mg/mL concentration were
prepared in water, PBS, and PBS + 10% FBS, in triplicate. UV/visible absorption spectra
were

obtained for

each of

the solutions in triplicate

using the UV/visible

spectrophotometer described above. The absorbance spectrum was normalized to a
maximum absorbance of 1. The hydrodynamic diameter of the solutions was measured
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using the Zetasizer described above. The number mean was reported for the
hydrodynamic diameter. Solutions were maintained at 25 °C. Both UV/visible spectra
and hydrodynamic size were measured at different time points; 0, 1, 3,7, and 14 days
post-dilution.

2.3.3.6 Inductively coupled plasma optical emission spectroscopy (ICP-OES)
ICP-OES (Spectro Genesis ICP) was used to determine the silver and tellurium
concentration in the nanoparticle formulation as previously described.9, 26 In brief, 10 µL
of Ag2Te NP stock solution were placed in 15 mL falcon tubes. The nanoparticles were
dissolved in 10% nitric acid. The final silver and tellurium concentrations in the stock
solution were obtained by multiplying the concentrations obtained by the ICP-OES by
their dilution factor.

2.3.3.7 Energy dispersive X-ray spectroscopy (EDX)
Similar to the transmission electron microscopy methodology, samples were
dried onto Formvar carbon-coated copper grids with 200 mesh. The samples were then
imaged using an FEI Quanta 600 field emission gun scanning electron microscope
equipped with EDX detectors. The equipment was operated at 15 kV.

2.3.3.8 X-ray powder diffraction (XRD)
The diffraction patterns of dried samples were recorded using a Rigaku
GiegerFlex D/Max-B X-ray diffractometer. The parameters used while operating the
diffractometer were the following: 45 kV, 30 mA, monochromatized Cu Kα radiation
wavelength of 1.5406 Å, scan range of 20-60°, and 2° per minute scan rate.
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2.3.3.9 X-ray photoelectron spectroscopy (XPS)
XPS analysis was conducted using a PHI Veraprobe 5000 instrument equipped
with a monochromated AlK alpha source. The following parameters were used: X-ray
setting was set to 200 microns, electron beam to 50W, while photoelectrons were
collected using a hemispherical analyzer. For survey scans, a pass energy of 117 V
was used. Dual beam neutralization was performed to compensate depletion of
photoelectrons from the surfaces as the charge compensation method.

2.3.3.10 Ag+ ion release
The release of Ag+ ions from Ag2Te nanoparticles was assessed as described
previously.102,

113

In brief, the nanoparticles were incubated at 37ºC in DI water or

simulated lysosomal fluid (citrate buffer at pH 5) at a concentration of 1mg/mL to a final
volume of 5 mL. The Ag+ ions were separated by centrifugation using a 10kDa MWCO
tube at each time point and measured via ICP-OES. Data is presented as mean ±
standard deviation.

2.3.4 Cell Assays
2.3.4.1 Cell culture
Hep G2 (human hepatocellular liver carcinoma), J774A.1 (murine macrophage),
and MDA-MB-231 (human breast cancer) cells were purchased from ATCC (Manassas,
VA, USA). Cells were cultured according to the supplier’s instructions at 37 C and 5%
CO2.
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2.3.4.2 In vitro cytotoxicity
Cell viability studies were performed as described elsewhere.9, 26 In brief, 80,000
cells were seeded in 35 mm dishes with 20 mm bottom well. These cells were incubated
for 24 hours in the appropriate cell culture media. After 24 hours, the cell culture media
was removed, cells were washed with DPBS, and a solution of Ag2Te or Ag
nanoparticles diluted in cell media at different concentrations was added. The
concentrations used in this experiment were 0.1, 0.5, and 1 mg Ag/mL. Cells were
incubated for 4 hours with the appropriate nanoparticle type and concentrations.
LIVE/DEAD assay (Invitrogen Life Technologies, Grand Island, NY) was used to
determine cell viability. Following the 4-hour incubation period, cells were washed with
sterile DPBS and 400 µL of a solution containing the live cell dye calcein-AM, dead cell
dye ethidium-1 homodimer, and nuclei dye Hoechst 33342 in DPBS was added. Cells
were incubated with this dye solution for 20 minutes. The cells were then imaged using
a Nikon Eclipse Ti-U fluorescence microscope with DAPI (ex: 359, em: 461 nm), FITC
(ex: 495, em: 519 nm), and Texas Red (ex: 595, em: 613 nm) filters to image nuclei, live
cells, and dead cells, respectively. Four phase images, as well as four images per filter,
were taken for each plate. The number of live and dead cells was measured using an inhouse developed MATLAB (MathWorks, Natick, MA) code. The viability percentage was
determined by the ratio of live cells to dead cells. The relative cell viability (% control) is
presented as mean  standard deviations for each concentration and cell line.

2.3.4.3 Reactive oxygen species (ROS) generation
To quantify the generation of reactive oxygen species in J774A.1 cells
(macrophages), a protocol similar to that previously described by our group was used.113
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In brief, 10,000 cells were plated in each well of a 96 well plate 24 hrs prior to the
experiments. The cells were then treated with Ag2Te, Ag2S, or Ag nanoparticles at
concentrations ranging from 0-1 mg/mL for 4 hrs. After the treatment time, the cell
monolayer was washed twice with PBS. 100 µL of CM-H2DCFDA (Invitrogen, Carlsbad,
CA, USA) at a 10mM concentration was then added to cells and incubated for 25 min.
Cells were then washed once with PBS. 100 µL of PBS was added to each well before
reading the fluorescence at excitation and wavelength of 492 nm and 527 nm,
respectively. 4 wells were counted as one sample, and three independent experiments
were done. Data is presented as mean% control ± standard deviation.

2.3.4.4 DNA damage
To quantify the DNA damage in cells after incubation with Ag2Te, Ag2S, and Ag
nanoparticles, a previously described protocol was followed.113 In brief, 1.5 x 106 cells
were plated in 6 well plates 24 hrs prior to the experiment, following ATCC
recommendations. The cells were then treated with the 3 different nanoparticles for 4
hrs at concentrations ranging from 0-1 mg/mL. After treatment, the cells were washed
twice with PBS and trypsinized or scraped to collect the cells.
The DNA of these cells was extracted following the Genomic DNA Isolation Kit
(ab65358) protocol from abcam (Cambridge, MA, USA).
To quantify the DNA damage in the isolated DNA, the protocol for DNA Damage
Assay Kit (ab211154) from abcam (Cambridge, MA, USA) was followed. This
colorimetric test quantifies the apurinic/apyrimidinic (AP) sites, a marker of DNA
damage. Data is presented as mean number of AP sites per 105 base pairs ± standard
deviation.
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2.3.5 Phantom imaging
2.3.5.1 Computed tomography
For CT phantom studies, solutions composed of Ag2Te NPs, silver (AgNO3),
tellurium (Na2TeO3), and iodine (iopamidol) at concentrations ranging from 0 to 10 mg of
the element of interest/mL were prepared and placed in small vials. PBS was used as a
negative control. Each solution was prepared in triplicate. These vials were then secured
in a plastic rack. The rack was then submerged in a plastic container holding 21 cm of
water to simulate the human abdominal cavity.

The samples were imaged using a

Siemens SOMATOM Force clinical CT scanner. The images were obtained at tube
voltages ranging from 80 to 140 kV in 20 kV increments with a tube current of 360 mA.
The field of view measured 37 x 37 cm while the slice thickness was 0.5 mm and the
matrix size was 512 x 512. The obtained images were then analyzed using OsirixMD.
The attenuation rates were calculated from the average of three slices per sample.

2.3.5.2 Dual-energy mammography
Dual-energy mammography images in a custom-designed wedge phantom
(Supplemental Figure 2-1) were acquired for the study. The phantom consists of a 4
cm-thick continuous gradient section composed of tissue-equivalent materials ranging in
composition from 100% glandular tissue to 100% adipose tissue, as previously
described.27 Solutions of Ag2Te NPs, iodine (in the form of iopamidol), silver salt
(AgNO3), and tellurium salt (Na2TeO3) were loaded into polyethylene tubes at a
concentration of 10 mg of the element of interest/mL; PBS was used as a control. The
tubes were inserted into the phantom in the direction of varying tissue composition.
Images of the phantom were then acquired using a prototype DE Hologic Selenia
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Dimensions mammography system. The imaging system consists of an x-ray source
with a tungsten target and an energy-integrating selenium detector. Low-energy (LE)
images of the phantom were acquired at 29 kV using a silver filter at 100 mAs; Highenergy (HE) images of the phantom were acquired at 38 kV using a copper filter at 90
mAs. Each tube was imaged in triplicate.
DE image subtraction was performed to eliminate variations in the tissue
background so that we could differentiate the attenuation of the contrast agent signal
from the soft tissue signal. DE images of the phantoms were obtained by a weighted
logarithmic subtraction of the HE and LE image pairs. The DE subtraction process and
contrast-to-noise (CNR) calculations are described in further detail in our previous
works.26, 27

2.3.6 In vivo experiments
2.3.6.1 Animal tumor model
All animal procedures were performed in accordance with the Guidelines for
Care and Use of Laboratory Animals and approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Pennsylvania.
For in vivo assessments, an orthotopic tumor model was developed. For this, 2.5
x 106 MDA-MB-231 cells were implanted in the fourth mammary pads of 12 nude female
mice. Tumor growth and mouse health were monitored weekly. Tumor volume was
measured with calipers and calculated using the following equation: Tumor volume = ½
(length x width2). Mice with tumors with an average volume of 100 mm3, were injected
via the tail vein with Ag2Te NPs or Ag2S NPs (as a control) at a dose of 250 mg/kg (190

55

µL injection volume). This dose was chosen since it is comparable to the iopamidol dose
used for patients.28 Isoflurane was used to anesthetize mice during all experiments.

2.3.6.2 Computed tomography
In vivo CT imaging was performed using a Molecubes X-Cube micro-CT scanner.
Images were acquired using the following parameters: 50 kVp, 100uA, 85ms exposure,
and 480 projections. Images were reconstructed through a software provided by the
manufacturer and using 100 um isotropic voxel reconstruction with a noise regularization
factor of 3. Mice were scanned before injection, 2 hours post-injection, and 24 hours
post-injection. The obtained images were analyzed using OsirixMD. For the analysis,
ROIs were drawn in the organs of interest, and the attenuation values (HU) were
recorded. The data is presented as the change in attenuation from pre-injection scans as
mean ± standard deviation.

2.3.6.3 Biodistribution
The biodistribution experiment was performed in 10 female wild-type mice. 24
hours post-injection, mice were euthanized with CO2 gas for 10 minutes according to the
IACUC-approved protocol. Mice were then dissected and tissue from the heart, liver,
kidney, spleen, and lungs were collected and their weights were recorded. These tissues
were then minced and subjected to acid digestion with 2 mL of nitric acid overnight at 75
ºC. The samples were then diluted to a final volume of 10 mL with DI water. The silver
and tellurium concentrations were measured for the tissue of mice injected with Ag2Te
NPs while the silver concentration was measured for tissue from mice injected with Ag2S
NPs. The concentration of metals was determined through ICP-OES. An average of 5
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mice per group were analyzed. Biodistribution data is presented as mean ± standard
error of mean (SEM).

2.3.6.4 Histology
Following mice euthanasia, tissues from the major organs (heart, liver, spleen,
lung, and kidney) of 2 mice per group, were collected and sliced into 5-6 mm in
thickness while placed in chilled PBS. Tissues were immediately fixed in a 10% formalin
solution at 4 °C overnight. The samples were then dehydrated, embedded, sectioned,
and stained with hematoxylin and eosin (H&E) by the Children’s Hospital of Philadelphia
Pathology Core.

2.3.6.5 Statistical Analysis
All the experiments were performed independently at least three times. In all
figures, data points represent the mean, while the error bars represent standard
deviations from the mean or the standard error of mean, as specified. Tukey’s multiple
comparisons test was used when comparing the stability of Ag2Te NPs via size
measurements, the CNR of different solutions in the DEM phantom, and the attenuation
rate of the different solutions under CT. Unpaired t-tests were used to compare between
cell viability data from Ag and Ag2Te NPs and when comparing among Ag2Te and Ag2S
in vivo CT attenuation. P values ≤ 0.05 were considered statistically significant.
Statistical analysis was carried out using GraphPad Prism 8 software (San Diego,
California USA).

57

2.4 Results and Discussion
2.4.1 Synthesis and characterization of Ag2Te NPs
Ag2Te nanoparticles were synthesized as depicted in Figure 2-1A, where silver
nitrate and sodium tellurite were used as silver and tellurium precursors, respectively,
and reduced by hydrazine dihydrate. The Ag2Te NPs were coated with 5K polyethylene
glycol thiol (mPEG-SH) for improved stability, biocompatibility, and blood circulation halflife. Electron micrographs from the resulting nanoparticles are shown in Figure 2-1B
and 2-1C. The nanoparticle core size, measured from the electron micrographs, was
found to be in 8  2 nm in diameter, while the hydrodynamic diameter was determined to
be 17  5 nm via DLS measurements, as summarized in Figure 2-1D. This difference in
diameter between the core and the hydrodynamic diameter is expected due to the PEG
coating and is in agreement with previous reports of PEG-SH 5K coated nanoparticles.
For example, Silvestri, et al. has reported a difference of 11 nm while Chen et al.
reported an increase of 6 nm.25,

29

The Z-potential of the nanoparticles was also

measured and resulted in -14.9  0.8 mV, which is consistent with other reports of
slightly negative or neutral PEGylated nanoparticles.26, 30-32 11-mercaptoundecanoic acid
(11-MUA) coated Ag2Te NPs were synthesized as a control nanoparticle with an anionic
surface, and their Z-potential was found to be -48 ±10 mV. To further characterize the
Ag2Te NPs, their UV-vis spectrum was recorded and is shown in Figure 2-1E. This
broad spectrum reveals a profile characteristic of Ag2Te nanoparticles where no
prominent peak is observed,16, 33 as compared to pure silver nanoparticles (Ag NPs) that
have a peak at a wavelength of near 400 nm. We further characterized the optical
properties of our Ag2Te NP formulation, specifically their fluorescence properties.
Although other silver chalcogenide nanoparticles have been previously reported to yield
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fluorescence in the NIR regions, we did not observe fluorescence from this formulation.
34, 35

We hypothesize that this is due to the synthesis being carried out in aqueous

conditions, which have been previously reported to result in low fluorescent yields. 34, 36

Figure 2-1: Ag2Te nanoparticle synthesis and characterization. A) Schematic depiction
of Ag2Te NP synthesis. B) Transmission electron micrograph of Ag2Te NPs. C) Highresolution micrograph of Ag2Te NPs. Scale bar: 5 nm. D) Table summarizing Ag2Te NP
core diameter, hydrodynamic diameter (HD), and z-potential values. E) UV-visible
absorbance spectrum of Ag2Te NPs.
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To investigate the composition of the Ag2Te NPs further, we performed energy
dispersive x-ray spectroscopy (EDX). The obtained spectrum is presented in Figure 22A. In this spectrum, we can observe peaks at an x-ray energy of 2.98 keV, 3.77 keV,
and 2.3 keV corresponding to silver, tellurium, and sulfur, respectively. Furthermore, the
silver and tellurium peaks show a 2:1 ratio, as expected. ICP-OES measurements also
confirmed the 2:1 ratio of silver to tellurium (data not shown). To further characterize the
Ag2Te NPs, an XRD spectrum was obtained and shown in Figure 2-2B. Although broad
peaks are observed due to the small size of the nanoparticle core, the strong peaks at
27, 36, and 41 2θ degrees closely match that of previously reported Ag2Te XRD
patterns37, 38, while the peak at 24 2θ degrees matches that of PEG.39, 40 Moreover, the
Ag2Te nanoparticles were further characterized using XPS. The resulting spectra are
presented in Figure 2-2C-E. This data further confirms the oxidation of Ag and the
presence of Te in the samples. The peaks at 366.4 eV and 372.4 eV correspond to Ag
3d 5/2 and Ag 3d 3/2, respectively, while those at 570.4 eV and 581.4 eV correspond to
Te 3d 5/2 and Te 3d 3/2, respectively.
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Figure 2-2: Nanoparticle characterization. A) Energy dispersive x-ray and B) XRD
spectrum of Ag2Te nanoparticles. C-E) XPS pattern of Ag2Te NPs. C) Survey spectrum.
D) Ag 3d and E) Te 3d high-resolution spectra.
An important characterization assay to aid in predicting nanoparticle in vivo
performance is the determination of the stability of the nanoparticles in biologically
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relevant media. To test this, the nanoparticles were incubated in DI water, PBS, and
PBS + 10% FBS to assess their stability in the absence and presence of ions as well as
in the presence of both ions and serum proteins. These different solutions were
analyzed with UV-vis (Figure 2-3A-C) and DLS (Figure 2-3D-F) since these two
techniques are sensitive to particle size and concentration. The solutions were incubated
at room temperature for fourteen days. As shown in Figure 2-3, there was no significant
change in the UV-vis spectra from the initial incubation time over this time period.
Similarly, no significant difference was observed in the hydrodynamic diameter or core
size (Supplemental Figure 2-2) in any of the media tested. We further looked into the
XRD spectra of these particles in the different media over 14 days, with no differences
observed in the spectra over time (Supplemental Figure 2-3). These results show the
high stability of these nanoparticles in the different conditions and, more importantly, in
PBS + 10% FBS, which more closely represents the in vivo conditions. To further
investigate the degradation of Ag2Te nanoparticles, we incubated them in water and
simulated lysosomal fluid, and measured the release of Ag+ ions. Results are presented
in Figure 2-4A. Our results are in agreement with previous reports where Ag2S released
fewer Ag+ ions in both conditions compared to Ag nanoparticles.10 The stability data of
PEG-SH 5K coated Ag2Te NPs, together with other characterizations including the close
to neutral Z-potential, XRD peak at 24 2θ degrees, EDX sulfur peak, and FT-IR (Figure
2-4B), suggest the successful PEGylation of the Ag2Te nanoparticles.31, 39, 40
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Figure 2-3: Ag2Te nanoparticle colloidal stability. UV-Vis spectra of Ag2Te nanoparticles
incubated in A) DI water, B) PBS, and C) PBS + 10% FBS for 14 days. The dark blue
curve shows data from day 0, red from 24 hrs, blue from 3 days, green from 7 days, and
purple from 14 days post-incubation in the different media. The hydrodynamic diameter
of Ag2Te nanoparticles in D) DI water, E) PBS, and F) PBS + 10% FBS. Data is
presented as the mean, while the error bars represent standard deviations.
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Figure 2-4: Ag+ release and FT-IR characterization. A) Percentage of cumulative Ag+ ion
release of Ag2Te nanoparticles incubated in DI water and simulated lysosomal fluid
(citrate buffer) over time. B) FTI-R spectra of mPEG-SH 5K (black), mPEGSH-5K coated
Ag2Te nanoparticles (red) and mPEG-SH 5K coated Ag2S nanoparticles (blue).

2.4.2 Ag2Te nanoparticles show no acute toxicity when incubated with different cell
lines.
Prior to in vivo testing, an in vitro assay was conducted where nanoparticles were
incubated with different cell types. For this, we studied the effect of the nanoparticles in
the viability of specific cell types where they are predicted to accumulate. Due to their
size, these nanoparticles are predicted to accumulate in the reticuloendothelial system
(RES) organs such as the liver and spleen.41-43 These nanoparticles should also
accumulate in the tumor due to the enhanced permeability and retention (EPR) effect.
For this reason, we studied the viability of liver, macrophage, and breast cancer tumor
cell lines after incubation with the nanoparticles. Furthermore, the effect of Ag2Te NPs in
these different cell lines was compared to that of pure silver nanoparticles (Ag NPs),
which have been shown previously to be toxic to cells due to their release of pure silver
ions.44 As an additional control, the viability of cells after incubation with Ag2S NPs was
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also measured. For this, Ag NPs and Ag2S of the same size and coating were
synthesized, and their characterization is presented in Figures 2-5 and Supplemental
Figure 2-4, and Figure 2-6 and Supplemental Figure 2-5, respectively. In this
experiment, the different cell types were incubated with Ag2Te NPs and Ag or Ag2S NPs,
as controls, for 4 hours (Figure 2-7A-C). The cytotoxic effect of the Ag NPs in all three
cell lines at concentrations higher than 0.1 mg Ag/mL is readily apparent. In contrast, no
acute toxicity was observed with Ag2Te NPs (no significant difference from control) with
all three cell lines up to the highest concentration tested (i.e., 1 mg Ag/mL). Similar
results were obtained from Ag2S NPs, in agreement with previous reports.9 To further
look into the biocompatibility of these nanoparticles, we have included the data on the
generation of ROS and DNA damage in macrophages. Results are presented in Figures
2-7D and 2-7E. Increase ROS generation can be observed for Ag nanoparticles
compared to Ag2Te and Ag2S at 0.25 mg/mL, whereas at higher concentrations, the
decrease in ROS is supported by our cell viability data where these cells are no longer
viable and thus, we detect lower levels of ROS. These data support our cell viability data
where no acute toxicity was observed after incubation with Ag2Te nanoparticles as
compared to Ag nanoparticles and the similarity in biocompatibility with Ag2S
nanoparticles.
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Figure 2-5: Synthesis and characterization of Ag NPs. A) Schematic of Ag NP synthesis.
B) TEM micrograph of Ag NPs, core size, and Z-potential data. C) UV-Vis spectrum of
Ag NPs. D) Energy dispersive X-ray spectrum of Ag NPs. E) X-ray dispersive spectrum
of Ag NPs.
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Figure 2-6: Synthesis and characterization of Ag2S NPs. A) Schematic of Ag2S NP
synthesis. B) TEM micrograph of Ag2S NPs, core size, hydrodynamic diameter, and Zpotential data. C) UV-Vis spectrum of Ag2S NPs. D) Energy dispersive X-ray spectrum of
Ag2S NPs. E) X-ray dispersive spectrum of Ag2S NPs.
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Figure 2-7: In vitro biocompatibility of Ag2Te compared to Ag2S and Ag nanoparticles.
Viability of A) HepG2, B) MDA-MB-231 and C) J774A.1 cells after incubation with Ag2Te
(black bars), Ag2S (dark gray) or Ag NPs (silver bars) for 4 hours at different
concentrations. D) ROS generation of J774A.1 cells when incubated with Ag2Te, Ag2S,
and Ag nanoparticles at different concentrations. E) DNA damage of HepG2 cells when
incubated with Ag2Te, Ag2S and Ag nanoparticles at a concentration of 0.25 mg Ag/mL
for 4 hrs. Error bars represent standard deviations. *P-value < 0.05. ** P-value < 0.01
**** P-value < 0.0001.

2.4.3 Ag2Te NPs generate higher contrast in CT and DEM phantoms compared to silver
and iopamidol
The ability of Ag NPs to be used as x-ray contrast agents has been previously
investigated.25, 42 It has been shown that Ag NPs can produce slightly less contrast in CT
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and 40% higher contrast in DEM compared to iodinated molecules currently used in the
clinics.25, 45 Similarly, Hsu et al. have shown that, using the same imaging equipment as
this study and with similar parameters, Ag2S NPs produce comparable x-ray contrast to
Ag.10 Here, we explored the x-ray contrast of Ag2Te NPs in two main x-ray imaging
modalities: CT and DEM. To test the contrast generation of Ag2Te NPs in comparison to
Ag NPs in both x-ray imaging modalities, experiments using custom-made phantoms
were conducted (Figure 2-8).
For CT imaging, the phantom containing the different agents was imaged using a
clinical CT system at x-ray energies ranging from 80 kV to 140 kV. Figure 2-8A shows
representative images of the different solutions acquired at an x-ray energy of 80 kV.
The attenuation rate for Ag2Te NPs was higher than that of iopamidol and the other
controls, i.e., silver nitrate and sodium tellurite, at all studied energies (Figure 2-8B).
For the DEM experiments, the LE and HE energy combinations were explored to
find the one yielding the highest contrast for Ag2Te (Supplemental Figures 2-6 to 2-9).
From this optimization experiment, we selected the energy combination of 29 kV (LE)
and 38 kV (HE). Figure 2-8C shows phantom images at LE of 29 kV, HE of 38 kV, and
the DE subtraction image. Figure 2-8D shows the quantification of the contrast-to-noise
ratio (CNR) of the DE subtraction image for the different solutions. Ag2Te NPs exhibit
higher CNR than either silver alone or iopamidol, at this LE and HE energy pair (note
that we used silver nitrate as a control, which previous experiments have shown to have
identical contrast generation to Ag2S NPs10). Together these phantom studies show that
Ag2Te NPs exhibit higher contrast than either iopamidol or silver nanoparticles without
tellurium and suggest that they could be used as x-ray contrast agents. Of course, this
observation is due to the presence of tellurium in Ag2Te NPs, but underscores the
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benefit resulting from ensuring that both elements in the formulation are contrast
generating.

Figure 2-8: In vitro imaging with CT and DEM. A) DEM phantom imaging at a LE of 29
kV, HE of 38 kV, and DEM subtraction image. B) DEM phantom image contrast-to-noise
ratio (CNR) quantification. Ag denotes AgNO3 salt, Te denotes Na2TeO3 salt, and I
denotes iopamidol. PBS was used as a negative control. The different solutions had a
concentration of 10 mg of the element of interest/mL (Ag2Te NPs had a concentration of
10 mg of Ag/mL to facilitate comparison). C) CT phantom image at 80 kV.
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D)

Quantification of the CT attenuation rate of the different solutions at different energies.
Error bars represent standard deviation. **** P ≤ 0.0001.

2.4.4 Ag2Te NPs lead to high CT contrast in breast cancer tumor-bearing mice
Our group has previously developed several silver-based DEM and CT contrast
agents.9, 10, 26 Among these, silver sulfide nanoparticles (Ag2S NPs) have shown promise
in their use as DEM and CT contrast agents since they produce contrast, in vivo, similar
to that of pure silver nanoparticles, but without undesired side effects.9, 10 To test the in
vivo contrast of the Ag2Te NPs, we developed a mouse model by inoculating MDA-MB231 breast cancer cells to the mice mammary glands. To compare the in vivo contrast
generation of Ag2Te NPs with that of Ag2S, we developed Ag2S NPs of the same size
and coating (5K mPEG-SH) (Figures 2-5 and 2-6), since this should yield similar
pharmacokinetics and, therefore tumor accumulation for both formulations. Tumorbearing mice were injected with Ag2Te NPs or Ag2S NPs (as a control) at a dose of 250
mg Ag·kg-1 (190 µL injection volume). The tumor-bearing mice were imaged with microCT prior to injection and at 2 hrs post- and 24 hrs post-injection. Representative CT
images of the heart of tumor-bearing mice at different time points injected with Ag2Te
NPs are displayed in Figure 2-9A. As presented in Figure 2-9B, an increase in contrast
is observed in the heart 2 hrs post-injection. The contrast in the heart can still be
observed 24 hrs post-injection. The long circulation time of Ag2Te NPs suggests their
potential use as blood pool agents for imaging. As expected with nanoparticles of this
size, and as shown in Figures 2-9A and 2-10A, accumulation was observed in the liver
and spleen over 24 hours in both nanoparticle formulations.26 Moreover, we found the
CT attenuation to be higher (compared to pre-injection scans) in the tumors of mice
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injected with Ag2Te NPs than in those of mice injected with Ag2S NPs at 2 hrs and 24hrs
post-injection (Figures 2-9C-D). No significant difference was found between the NP
accumulation in the tumors of mice injected with Ag2S and Ag2Te (Figure 2-10B). This
increase in attenuation is as we expected, given the phantom imaging results.

Figure 2-9: In vivo CT imaging of breast cancer tumor-bearing mice. A) Representative
CT scan images at the level of the heart from a mouse injected with Ag2Te NPs, at
different time points: pre-injection, 2 hrs post-injection (2 hrs p.i.) and 24 hrs postinjection (24 hrs p.i.). B) Quantification of the change in CT attenuation (difference
between pre-injection and the different time point images) in the major organs of mice
injected with Ag2Te NPs. C) Representative images of CT scans from tumor-bearing
mice injected with Ag2Te NPs (top row) or Ag2S NPs (bottom row). Tumors are
highlighted in yellow circles. ROIs matching the outlines of the tumors were used for
image analysis. D) Quantification of the change in CT attenuation in the tumors from
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mice injected with Ag2Te or Ag2S NPs. Error bars represent standard deviation.
Statistical comparisons are versus pre-injection scans. *P < 0.05.

2.4.5 Ag2Te NPs accumulate in RES organs and don’t show signs of acute toxicity
To further investigate the nanoparticle biodistribution, mice were sacrificed 24 hrs
post-injection. The organs of both mice groups were collected, and their nanoparticle
content was measured through ICP-OES. We found substantial accumulations of Ag2Te
and Ag2S NPs in the liver and spleen, as expected for nanoparticles of this size46
(Figure 2-10A). We observed similar biodistributions for both nanoparticle formulations,
which suggests that the observed differences in contrast could be attributed to the
incorporation of tellurium to the formulation. In addition, no significant difference was
found between the NP accumulation in the tumors of mice injected with Ag2S and Ag2Te
(Figure 2-10B).
To examine the biocompatibility of Ag2Te NPs in vivo, we collected sections of
tissue of the tumor-bearing mice 24 hours post-injection and performed hematoxylin and
eosin (H&E) staining. Tissues from mice injected with PBS were used as controls
(Figure 2-10C). No apparent changes were observed in the tissue structures of Ag2Te
NP-injected mice, with similar morphology found for Ag2S NPs and PBS-injected mice.
These findings support the biocompatibility of the Ag2Te NPs in vivo.
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Figure 2-10: Biodistribution and histology. A) Biodistribution of Ag2Te and Ag2S NPs in
major tissues and organs of injected mice. Error bars represent standard error of mean
(SEM). B) Quantification of the NP accumulation in tumors of mice injected with Ag2S
and Ag2Te NPs. Data is presented as percent of injected dose (%ID). C) Representative
micrographs of tissue from major organs, after H&E staining, of mice injected with saline
(top row), Ag2S NPs (middle row), and Ag2Te NPs (bottom row).
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2.5 Discussion
Despite the beneficial optical properties of Ag2Te NPs, similar to those reported
with other silver chalcogenides, these nanoparticles have not been widely explored for
their potential biomedical applications. Up-to-date, only one other group has reported the
application of these NPs for biomedical applications in vivo.21 In the study, Zhang et al.
report the intense fluorescence signal and biocompatibility of Ag2Te quantum dots
encapsulated in poly(lactic-co-glycolic acid) (PLGA) and coated with cell membranederived vesicles. However, this double layer of encapsulation, including the use of a
hydrophobic polymer, will limit the possibility of contact of these Ag2Te quantum dots
with mammalian cells compared with the agents reported in the current study. Moreover,
the concentrations used in that study were quite low compared to the concentrations
tested in this study. A maximum concentration of particles of 200 µg ml-1 in the
biocompatibility assays and a silver dose of 2 mg kg-1 for in vivo experiments were
reported. Although these low concentrations are appropriate for more sensitive
applications such as fluorescence imaging, many other biomedical applications require
much higher doses, such as radiosensitization or photothermal therapy.47-52 Herein, we
have explored Ag2Te NPs’ biomedical application in the setting requiring the highest
nanoparticle dose, i.e., x-ray imaging.
In this study, we have developed Ag2Te NPs of hydrodynamic diameter of 17 ± 5
nm. These nanoparticles not only have excellent biocompatibility with the studied cell
lines and in vivo, but also generate superior x-ray contrast compared to previously
reported silver or silver sulfide nanoparticles.9, 10, 26, 45 This excellent biocompatibility is
likely due in part to their PEGylation, which is known to prevent adverse reactions to
exogenous materials, but is also likely due to the extremely low solubility product of
Ag2Te. This is evidenced from the in vitro biocompatibility studies, where we observed
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reductions in the viability of cells for pure silver nanoparticles, in agreement with prior
reports,43, 51 but not with Ag2Te or Ag2S NPs. Histology also shows no acute toxicity in
the tissue of mice injected with Ag2Te. Meanwhile, the high x-ray contrast generating
capacity of these NPs, both in vitro and in vivo, can be largely attributed to the
combination of silver and tellurium in the nanoparticles. Our results show higher contrast
from Ag2Te NPs than would be expected from summing the contributions of the
individual elements (Figure 2- 8D). This could be due to a phenomenon reported by Kim
et al. where nanoparticle contrast agents composed of multiple metals generated higher
contrast in CT than the individual elements.53
We observed high accumulation in the liver and spleen 24 hours post-injection
when analyzing the nanoparticle's biodistribution. These values are expected due to the
nanoparticle’s hydrodynamic diameter above the kidney’s glomerular filtration threshold
(about 5.5 nm).46 Thus, Ag2Te NPs are expected to undergo hepatobiliary elimination,47
which is an extremely slow process and therefore, Ag2Te NPs are expected to remain in
the body for an extended period.54, 55 Clinical translation requirements include complete
clearance in a reasonable time.40,
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To improve clinical translatability, reducing the

hydrodynamic diameter of Ag2Te NPs to one allowing kidney/urinary clearance will be
desired. Moreover, while our biocompatibility results are encouraging, more extensive
studies, such as blood chemistry, repeated dosing, long-term biodistribution, and
assessments in larger animal models will be needed to definitively establish safety. In
addition, biocompatibility is known to depend on various factors, such as size, shape,
and coating, therefore in vitro and in vivo studies will need to be completed for any new
Ag2Te NP formulations. Despite the additional work to be done, our studies provide a
good indication of the biomedical applications and translatability of these nanoparticles.
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2.6 Conclusion
For the first time, Ag2Te NPs have been explored in the in vivo setting requiring
the highest dose of all biomedical applications: x-ray imaging. Moreover, we have shown
the potential utility of these nanoparticles as contrast agents for breast cancer screening.
Ag2Te NPs showed no acute toxicity in vitro or in vivo, as shown by cell viability studies
and histological analysis, respectively. Their biocompatibility at this very high dose points
to the likelihood that Ag2Te NPs will prove to be biocompatible for their many other
possible biomedical applications that require lower doses. Furthermore, CT and DEM
phantom studies and in vivo CT imaging of breast cancer tumor-bearing mice revealed
high contrast generation from Ag2Te NPs as compared to controls such as a silver salt
or Ag2S NPs. Moreover, higher contrast was observed in tumors of mice injected with
Ag2Te NPs when compared to Ag2S NPs in CT imaging. Ag2Te NPs’ good
biocompatibility, enhanced contrast, as well their blood pool agent characteristics show
their potential to be used in biomedical applications and, more specifically, as contrast
agents for breast cancer screening.
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2.8 Supplemental Figures
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Supplemental Figure 2-1: DEM wedge phantom photograph.

Supplemental Figure 2-2: TEM micrographs of Ag2Te nanoparticles incubated in
different media over time.
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Supplemental Figure 2-3: XRD patterns of Ag2Te nanoparticles incubated in A) water, B)
PBS, and C) PBS+ 10% FBS over time.
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Supplemental Figure 2-4: XPS pattern of Ag nanoparticles. Spectra showing A) survey
scan, B) Ag 3d, C) C 1s, and D) O 1s high-resolution spectra.
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Supplemental Figure 2-5: XPS pattern of Ag2S nanoparticles. Spectra showing A)
survey scan, B) Ag 3d, C) S 2p, D) C 1s, and E) O 1s high-resolution spectra.
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Supplemental Figure 2-6: Contrast-to-noise (CNR) ratio quantification of DEM phantom
images at different energy combinations for AgNO3 solutions at a concentration of 10 mg
of Ag/mL. H denotes high energy and L denotes low energy.

Supplemental Figure 2-7:Contrast-to-noise (CNR) ratio quantification of DEM phantom
images at different energy combinations for Ag2Te solutions at a concentration of 10 mg
of Ag/mL. H denotes high energy and L denotes low energy.
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Supplemental Figure 2-8: Contrast-to-noise (CNR) ratio quantification of DEM phantom
images at different energy combinations for Iopamidol solutions at a concentration of 10
mg of iodine/mL. H denotes high energy and L denotes low energy.
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Supplemental Figure 2-9:Contrast-to-noise (CNR) ratio quantification of DEM phantom
images at different energy combinations for Na2TeO3 solutions at a concentration of 10
mg of Te/mL. H denotes high energy and L denotes low energy.
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Chapter 3: Renally excretable silver telluride nanoparticles as
contrast agents for x-ray imaging

3.1 Abstract
Nanoparticles in the biomedical field have gained much attention due to their
medical imaging, drug delivery, and therapeutics applications. Silver telluride
nanoparticles (Ag2Te NPs) have been recently shown to be highly effective computed
tomography (CT) and dual-energy mammography contrast agents with good stability,
biocompatibility, and potential for many other biomedical purposes. Despite their
numerous advantageous properties for diagnosis and treatment of disease, the clinical
translation of Ag2Te NPs depends on achieving high excretion levels, a limitation for
many nanoparticle types. In this work, we have synthesized and characterized a library
of Ag2Te NPs and identified conditions that led to 3 nm core size and were renally
excretable. We found that these nanoparticles have good biocompatibility, strong x-ray
contrast generation, and rapid renal clearance. Our CT data suggest that renal
elimination of nanoparticles occurred within 2 hours of administration. Moreover,
biodistribution data indicate that 93% of the injected dose (%ID) has been excreted from
the main organs in 24 hours, 95% ID in 7 days, and 97% ID in 28 days with no signs of
acute toxicity in the tissues studied under histological analysis. To our knowledge, this
renal clearance is the best reported for Ag2Te NP while being comparable to the highest
renal clearance reported for any type of nanoparticle. Together, the results herein
presented suggest the use of GSH-Ag2Te NPs as an x-ray contrast agent with the
potential to be clinically translated in the future.
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3.2 Introduction
Inorganic

nanoparticles

serve

many

important

functions

in

biomedical

applications such as bioimaging, drug delivery, biosensors, and photothermal and
photodynamic therapy for multiple diseases.1-4 Yet, their clinical translation has been
scant to date and is limited to the Food and Drug Administration (FDA) approval of
several iron oxide nanoparticles and CE Mark approval of hafnium oxide nanoparticles.57

One of the most important needs for clinical translation is the in-depth evaluation of the

nanoparticle’s in vivo fate over time, and their interaction with different host cells and
tissues.8, 9 Of particular importance is their interaction with the mononuclear-phagocytic
system

(MPS)

(previously

described

as the

reticuloendothelial

system).

The

macrophages in the MPS organs (e.g., liver and spleen) typically uptake nanoparticles
with a hydrodynamic diameter larger than 6 nm.10 Once engulfed by the MPS, clearance
of the nanoparticles is extremely slow, and thus, the nanoparticles could remain in the
host for an extended period leading to an increased risk of toxicity.9, 10
Renally excretable nanoparticles reduce the long-term safety concerns
associated with MPS nanoparticle uptake.11-14 Renal clearance of nanoparticles takes
advantage of the kidney’s glomerular filtration system to rapidly eliminate the particles
through the kidneys and urine, with minimal accumulation in the MPS.15 To achieve this,
nanoparticles are developed with a hydrodynamic diameter below the glomerular
filtration threshold of 5.5 nm while incorporating surface coatings that avoid serum
protein adsorption.11, 12 Nanoparticles with high serum protein adsorption can be taken
up by the macrophages in the MPS organs.16-18 Thus, avoiding serum protein adsorption
through zwitterionic coatings, for example, favors renal clearance.11, 19 Therefore, renally
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clearable nanoparticles would consist, preferably, of a sub- 5 nm size with zwitterionic
coating and would be rapidly eliminated with minimal interaction with MPS organs.
Silver chalcogenide nanoparticles (Ag2X NP, X= S, Te, or Se) have excellent
properties for use in multiple biomedical applications.20 Some of these properties include
1) optical properties and strong x-ray attenuation, 2) ease of surface functionalization,
and 3) ultra-low solubility products (Ksp Ag2S = 6 x 10-50, Ksp Ag2Se = 3 x 10-65, and Ksp
Ag2Te = 2 x 10-72) which leads to broad biocompatibility.20,

21

In a previous study, we

reported silver telluride nanoparticles (Ag2Te NPs) with a 16 nm hydrodynamic
diameter.22 These Ag2Te NPs were biocompatible in vitro and in vivo, even at the high
dose of 250 mg/kg of body weight used, which is appropriate for x-ray imaging. Their
biocompatibility at this high dose suggested their safe use in several biomedical
applications and their potential for clinical translation. However, their large size led to
their accumulation in the MPS organs (25.2% ID/g in the spleen and 15.1% ID/g in the
liver), raising potential concerns about their long-term safety. The challenge, therefore,
for clinical translation of these highly promising nanoparticles, is to devise syntheses that
result in ultrasmall sizes to allow sufficient renal clearance and study their safety over
time.
To facilitate the clinical translation of Ag2Te NPs, we present the development of
sub- 5 nm Ag2Te NPs with glutathione (GSH) as their coating. GSH is a zwitterionic
molecule that has facilitated the renal clearance of other types of nanoparticles.11, 23, 24
Here, we present the synthesis and characterization of the GSH-Ag2Te NPs, their x-ray
contrast generation, in vitro and in vivo biocompatibility, and long-term safety. Most
importantly, we evaluated whether the GSH-Ag2Te NPs met the requirements for renal
excretion, where we found that 93% of the injected dose (% ID) was excreted from the
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main organs in 24 hours, 95% in 7 days, and 97% in 28 days. To our knowledge, this
renal clearance is markedly higher than the previously recorded values to date for Ag2Te
and Ag2X NPs while being comparable to the highest renal clearance reported up to date
for all types of nanoparticles.12, 14, 23, 25-27

3.3 Materials and Methods
3.3.1 Materials
Silver nitrate (AgNO3) and L-glutathione reduced (GSH) were purchased from
Sigma Aldrich (St. Louis, MO). Sodium tellurite (Na2TeO3) and hydrazine hydrate (N2H4)
were purchased from Alfa Aesar (Haverhill, MA) and Acros Organics (Thermo Fisher
Scientific, NJ), respectively. Nitric acid was purchased from Fisher Chemical (Thermo
Fisher Scientific, Waltman, MA). Deionized water (DI) (Milli-Q at 18.2 MΩ cm) was used
throughout the experiments.

3.3.2 Synthesis of GSH-coated 3 nm silver telluride nanoparticles
3 nm core, GSH-coated Ag2Te NPs were synthesized by first placing an aqueous
solution (9 mL volume) containing 10 mM of AgNO3, 5 mM of Na2TeO3, and 30 mM of
GSH, in an ice bath. 1 mL of N2H4 was then added to the solution. The reaction was
allowed to proceed for 5 minutes under constant magnetic stirring. Next, the NPs were
washed thrice by centrifugation at 4,000 rpm using 3 kDa molecular weight cut-off tubes.
After the third wash, the particles were suspended in PBS and washed again as
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described above. The particles were then concentrated to 1 mL, filtered using 20 nm
filters, and then stored at 4 °C until further use.

3.3.3 Nanoparticle Characterization
3.3.3.1 UV-vis spectroscopy
The UV-vis spectra of the Ag2Te NPs were recorded using a Genesys 150
UV/Vis spectrophotometer (Thermo Scientific, USA). In brief, 5 µL of the concentrated
GSH-Ag2Te NPs were diluted in 995 µL of DI water.

3.3.3.2 Transmission electron microscopy (TEM)
TEM micrographs were obtained to measure the nanoparticle core size. For this,
we used a Tecnai T12 electron microscope operated at 100 kV. To prepare the samples,
10 µL of the nanoparticle solution at a 0.5 mg/mL concentration were added to a carboncoated copper grid with 200 mesh purchased from Electron Microscopy Sciences
(Hatfield, PA). The samples were then allowed to dry onto the grid. The core diameter
was measured using ImageJ (National Institutes of Health, Bethesda, MA).

3.3.3.3 Energy-dispersive X-ray spectrometry (EDX)
The samples were prepared similarly to those for TEM. In brief, 10 µL of the
sample were dried onto carbon-coated copper grids. Data was acquired at 15kV using a
FEI Quanta 600 field emission gun scanning electron microscope.
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3.3.3.4 X-ray diffraction spectrometry (XRD)
The diffraction patterns of the samples were acquired using a Rigaku MiniFlex Xray diffractometer operated at 45 kV, 30 mA, 1.5406° Cu Kα radiation wavelength, 2° per
minute scan rate, and 20-60° scan range.

3.3.3.5 Fourier transformation infrared (FT-IR) spectrometry
FTIR sample pellets were created by combining approximately 25 mg of the
sample with 100 mg of potassium bromide. The samples were then dried in an oven,
pulverized using a mortar and pestle, and embedded in the sample holder for analysis
using a Jasco FT/IR-480 plus spectrometer.

3.3.3.6 Inductively-coupled plasma optical emission spectroscopy (ICP-OES)
A Spectro Genesis ICP-OES was used to determine the concentrations of Ag
and Te in the samples. For this, 1 mL of nitric acid was added to 10 µL of concentrated
NP solution. The samples were allowed to digest over at least 1 hour, followed by the
addition of 8.99 mL of DI water.
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3.3.4 In vitro biocompatibility assays
3.3.4.1 Cell culture
Cell culture of liver (HepG2) and kidney (Renca) cells was performed as
recommended by the supplier, ATCC (Manassass, VA). In brief, 5% CO2 was used to
culture these cells at a temperature of 37 °C. The recommended cell media for each cell
line were supplemented with fetal bovine serum (FBS) (Corning, Tewksbury, MA) and
penicillin-streptomycin (Thermo Fisher Scientific, Waltham, MA).

3.3.4.2 LIVE/DEAD staining
Cell viability studies using LIVE/DEAD staining were performed as described
elsewhere.22,

28

In brief, 80,000 cells were plated on 35 mm round-bottom dishes 24

hours prior to the experiment. After 24 hours, the cell media was removed, and fresh
media (0 mg/mL control) or Ag2Te NPs at a concentration of 0.1, 0.25, 0.5, or 1 mg of
Ag/mL were added to the dishes. After 4 hours, the treatment was removed, and the
cells were washed once with sterile PBS. 400 µL of a solution containing Calcein AM,
Ethidium-1 homodimer, and Hoechst 33342 were added to the dishes and incubated for
20 minutes. After 20 minutes, the dishes were imaged using a Zeiss Axiovert
fluorescence microscope equipped with FTIC, Texas Red, and DAPI filters. Four phase
images and four images per filter were acquired for each dish. An in-house developed
MATLAB code was used to determine the number of live and dead cells. The
percentage of viable cells was determined by the live to dead cells ratio. The data was
then normalized to the control and is presented as percent of control and as mean ±
standard deviation.
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3.3.4.3 ROS generation colorimetric assay
ROS generation was determined using the general oxidative stress assay CMH2DCFDA (Invitrogen by Thermo Fisher Scientific, MD, USA). In brief, 10,000 cells were
seeded in each well of a 96-well plate 24 hours prior to the experiment. The cells were
incubated for 4 hours with either cell media (control) or GSH-Ag2Te NPs at different
concentrations (0.1, 0.25, 0.5, and 1 mg of Ag per mL). After 4 hours of incubation, the
cells were washed with sterile PBS and Incubated with CM-H2DCFDA for 25 minutes.
H2O2 diluted to 0.3% was used as a positive control for detecting oxidative stress.
Fluorescence from these samples was read using a Tecan M1000 plate reader at an
excitation wavelength of 492 nm and 527 nm emission wavelength. Data are presented
as relative fluorescence units ± standard deviation.

3.3.4.4 DNA damage assay
DNA damage was assessed using an immunofluorescence staining protocol to
detect γH2AX, an early marker of DNA damage. For this, 15,000 cells were seeded in
each well of an 8-well glass slide chamber 24 hours prior to the study. 24 hours later, the
cells were incubated with either cell culture media (0 mg/mL control) or treated, in
triplicate, with NPs at a concentration of 0.25, 0.5, or 1 mg of Ag per mL for 4 hours.
Cells were fixed with 4% paraformaldehyde, blocked, and incubated at 4°C overnight
with Phospho-Histone H2AX antibody (Cell Signaling, Danvers, MA). As positive
controls, cells were irradiated with a dose of 6 Gy delivered by a Precision X-Rad 320IX
Biological X-Ray Irradiator 30 minutes prior to fixation. After washing with PBS, cells
were incubated with an anti-rabbit AF 594 secondary antibody for 1 hour. Following
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mounting with Vectashield antifade mounting media containing DAPI, the slides were
imaged at 20X using a Zeiss AxioObserver Z1 equipped with DAPI and RFP filters.
Image J was used to analyze the fluorescence intensity of the RFP and DAPI images.
The mean intensity ratio was determined by calculating the ratio of RFP and DAPI
fluorescence intensities. Data are presented as the mean ratio of fluorescence intensity
from control ± standard deviation.

3.3.5 In vitro imaging
3.3.5.1 Computed tomography (CT) phantom imaging
CT phantom images were acquired as described elsewhere.12,

22

In brief, to

prepare the phantom, triplicate solutions silver (AgNO3), tellurium (Na2TeO3), Ag2Te
NPs, and iopamidol of concentrations ranging from 0-10 mg of the element of interest
per mL were prepared in 300 µL tubes and placed in a plastic holder. Tubes containing
PBS were used as negative controls. The phantom was then covered in parafilm and
submerged in 21 cm of water to simulate the human body thickness. The scans were
acquired using a Siemens SOMATOM Force clinical CT scanner using the following
parameters: 80, 100, 120, and 140 kV tube voltages, 360 mAs tube current, 37 x 37 cm
field of view, 0.5 mm thickness, and a 512 x 512 matrix. The obtained images were
analyzed using OsirixMD. A region of interest (ROI) was drawn in the tubes, and the
intensities were recorded. The attenuation rate for each sample was determined from
the average of three slices. Data is presented as attenuation rate ± standard deviation.
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3.3.6 In vivo imaging
3.3.6.1 Animal model
All animal procedures were performed following the Public Health Service (PHS)
Policy on Humane Care and Use of Laboratory Animals (Public Law 99-158) per the
University of Pennsylvania Guidelines for Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee (IACUC) of the University
of Pennsylvania under protocol number 805593.
Female nude mice were selected as the model for the experiments herein
presented. In each experiment, 5 mice were used per group. A dose of 250 mg of Ag per
kg of body weight of Ag2Te NPs diluted in saline was injected into the mice via the tail
vein.

3.3.6.2 Computed tomography (CT) imaging
In vivo CT imaging was performed using a MILabs (Utrecht, the Netherlands)
micro CT scanner. Scans were acquired pre-injection, 5 minutes, 30 minutes, 60
minutes, and 120 minutes post-injection. The imaging parameters used were 50 kVp,
210 uA, 75 ms exposure, 0.75-degree step, and 360-degree acquisition. The images
were reconstructed using the following parameters: 100 µm reconstruction with 150 um
gaussian post-filter. The obtained scans were analyzed using OsirixMD. ROIs were
drawn in each organ of interest, and the attenuation was recorded. The data is
presented as the change in attenuation from pre-injection images ± standard error of
mean (SEM).
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3.3.6.3 Biodistribution
5 female nude mice were euthanized per group, using CO2 gas for 5 minutes at
24 hrs, 7 days, or 28 days post-injections. Organs, i.e., liver, spleen, kidneys, lungs, and
heart, were collected along with feces and blood. The weights of these organs and
tissues were recorded. The mice organs/tissues were then digested in either 4 (lungs,
heart, bladder, and blood) or 6 mL (liver, spleen, and kidneys) of nitric acid and placed
overnight in an oven at 90 °C. The next day, the samples were diluted to a final volume
of 10 mL using DI water. The silver and tellurium concentrations were determined using
ICP-OES. Biodistribution data is presented as mean %ID ± SEM.

3.3.6.4 Histology
Following mice euthanasia with CO2 gas, tissue from the major organs of the
mice were collected and sliced, in chilled PBS, into slices 5 mm in thickness. The tissues
were then immediately fixed in 10% buffered formalin overnight at 4°C. The samples
were then processed and stained with hematoxylin and eosin (H&E) by the Children’s
Hospital of Philadelphia Pathology Core.

3.3.7 Statistical analysis
All experiments were performed at least three times, independently. Data is
presented as mean ± standard deviation (SD) or standard error of mean (SEM), as
specified in each graph. P values ≤0.05 were considered statistically significant.
Unpaired t-tests were used to compare the different groups in the CT phantom data.
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One-way ANOVA with Turkey’s comparison test was used to compare the different data
groups in the ROS generation, cell viability, DNA damage, in vivo CT, and biodistribution
experiments. Statistical analysis was carried out using Graphpad Prism 9 software (San
Diego, CA, USA).

3.4 Results
3.4.1 Synthesis and characterization of GSH coated Ag2Te nanoparticles
We sought to find the reaction conditions that led to ultrasmall Ag2Te NPs (< 5.5
nm renal clearance threshold) while maintaining good colloidal stability. To achieve this,
we varied the following parameters: the coating molecule used and its concentration,
reaction time, and reaction temperature. These reactions are summarized in
Supplemental Table S1. Note that while several of the 3-mercaptopropionic acid (3MPA)-coated formulations met the size requirements, they were not colloidally stable in
PBS or PBS with FBS over time. Based on the desired properties, the reaction
conditions that yielded the most stable, ultrasmall Ag2Te NPs are depicted in Figure 31A. In brief, a solution containing silver and tellurium precursors combined with GSH and
N2H4 as the capping and reducing agent, respectively, was prepared. This solution was
allowed to stir for 5 minutes in an ice bath. The resulting nanoparticles had a broad UVvis spectrum with no prominent peaks, which is characteristic of Ag2Te NPs (Figure 31B), and a core diameter of 3 ± 1 nm (Figure 3-1C).22,

29

To confirm the successful

coating of the nanoparticles with GSH, the ζ-potential of the GSH-Ag2Te NPs was
recorded and is presented in the inset of Figure 3-1C. This ζ-potential agrees with
previous studies that have reported a slightly negative ζ-potential in GSH-coated
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nanoparticles.30,

31

Moreover, to further confirm the nanoparticle composition and

successful coating with GSH, the EDX spectrum of the GSH-Ag2Te NPs was recorded.
Figure 3-1D shows the characteristic x-ray peaks for silver (Ag), tellurium (Te), and
sulfur (S), imparted by the GSH coating. These peaks confirm the composition of the
nanoparticles and the successful incorporation of GSH as the nanoparticle coating.
Figure 3-1E shows the FT-IR spectra of the NPs compared to pure GSH. These results
further confirm the successful GSH coating on the NPs. The XRD spectrum (Figure 31F) reveals peaks at 26 and 38 2θ degrees, which, while broader due to the small size of
nanoparticles, are in agreement with previous reports.32-34
Aside from the previously discussed characterization data, the stability of GSHAg2Te NPs in water, PBS, and PBS with 10% FBS after 48 hours of incubation was
studied through UV-vis spectroscopy due to its high sensitivity to changes in
nanoparticle size, concentration, and aggregation.35 The study was conducted for 48
hours because of the expected rapid clearance of these NPs in vivo. The UV-vis spectra
are presented in Figure 3-2. This data shows no change in the UV-vis spectra of the
samples compared to the initial incubation time (0 hrs) and thus shows the stability of the
nanoparticles in the different media over 48 hours.
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Figure 3-1: Nanoparticle synthesis and characterization. A) Nanoparticle synthesis
schematic. B) UV-vis spectrum of GSH-coated Ag2Te NPs. C) TEM micrograph of GSHcoated Ag2Te NPs. Inset shows the core size and ζ-potential data for GSH-coated Ag2Te
NPs. D) EDX spectrum of GSH-coated Ag2Te NPs. E) FT-IR spectra of GSH and GSHAg2Te NPs. F) XRD pattern of GSH-coated Ag2Te NPs.

Figure 3-2: GSH-Ag2Te nanoparticle stability over time. UV-vis of GSH-Ag2Te
nanoparticles dispersed in A) water, B) PBS, and C) PBS + 10% FBS.

3.4.2 GSH-Ag2Te NPs are biocompatible with kidney and liver cells

An important requirement to facilitate clinical translation is the biocompatibility of
the nanoparticles with the host. As a marker for the biocompatibility of GSH-Ag2Te NPs
in vivo, we performed in vitro studies in cells from two of the main organs where renally
excretable nanoparticles have been shown to interact the most: kidney (Renca cells) and
liver (HepG2 cells).12,

36

We examined three biocompatibility parameters that better

predict in vivo biocompatibility.37 We first studied cell viability after incubation of the cells
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with the GSH-Ag2Te NPs. For this, Renca (kidney) and HepG2 (liver) cells were
incubated with different concentrations (0, 0.1, 0.25, 0.5, and 1 mg of Ag per mL) of
GSH-Ag2Te for 4 hours, followed by LIVE/DEAD assay staining. Results from this assay
are presented in Figure 3-3A. As shown in these figures, GSH-Ag2Te were
biocompatible (not statistically significantly different from control) with both cell lines,
where we observe close to 100% cell viability after 4 hours of incubation with the GSHAg2Te NPs, even at the highest concentration (1 mg of Ag/mL). This concentration, while
relevant to CT imaging, is much higher than those required by other biomedical
applications such as fluorescence imaging, photothermal therapy, and photodynamic
therapy, where concentrations in the µg/mL dose range are used. These results could
speak to the future translation of these particles to different biomedical applications. In
addition, the results are in agreement with previous reports on Ag2Te NPs and other
silver chalcogenide particles.12, 20, 22
Another important parameter to determine the biocompatibility of the GSH-Ag2Te
NPs with different cell types studied herein was the generation of reactive oxygen
species (ROS). High ROS generation has been proven to be a common toxicity issue in
the nanoparticle field, which could limit or impede their clinical translation.38,

39

ROS

generation leads to toxicity in cells due to oxidative stress and thus can cause damage
to cell organelles (including the mitochondria), DNA, cell membranes, ion channels, and
cell receptors.38,

39

Here, we studied the ROS generation of GSH-Ag2Te, at different

concentrations, in the two above mentioned cell lines after 4 hours of nanoparticle
incubation. H2O2 was used as a positive control. Figure 3-3B shows the results from the
ROS generation assay. These results showed no increase in ROS generation after
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incubation with different concentrations, even at the highest studied concentration (1 mg
of Ag per mL). These results are in agreement with results from our previous studies.22
The third assay to study the biocompatibility of these nanoparticles was their
effect on DNA damage. For this, the GSH-Ag2Te NPs were incubated for 4 hours at
different concentrations (0, 0.25, 0.5, and 1 mg of Ag per mL) with the above-mentioned
cell lines. After the 4-hour incubation period, DNA double-strand breaks were detected
by phospho-histone H2AX (γH2AX) immunofluorescence. Results from our study are
presented in Figure 3-3C. Here, we can observe that ≥ 0.5 mg of Ag per mL for Renca
cells and ≥ 1.0 mg of Ag per mL for HepG2 cells of GSH-Ag2Te NPs result in increases
of this marker. Although we see significant DNA damage at high GSH-Ag2Te
concentrations, the low ROS generation and viability results have led us to hypothesize
that the observed DNA damages could be repaired by the cells, as it is common for cells
to activate DNA repair mechanisms, or DNA damage response, to sustain genomic
integrity after any potential threat.40 In addition, the extensive in vivo clearance
discussed below, observed in CT images as early as 5 to 30 minutes post-injections,
suggests a low probability of reaching these high nanoparticle concentrations in the cells
in an in vivo setting.
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Figure 3-3: In vitro biocompatibility assays. A) Viability of kidney (Renca) and liver
(HepG2) cells in gray and blue, respectively, B) ROS generation of kidney cells and liver
cells in gray and blue, respectively, and C) immunofluorescence staining of γH2AX in
kidney and liver cells, in gray and blue, respectively, after incubation with GSH-coated
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Ag2Te NPs at different Ag concentrations. In panel C, + denotes positive controls (cells
irradiated with a dose of 6 Gy 30 minutes before staining). Data presented as mean ±
SD. Statistical significances are compared to the control. * p <0.05. **** p < 0.0001.

3.4.3 In vitro CT imaging of GSH-Ag2Te NPs resulted in strong x-ray attenuation
To test the x-ray contrast generating properties of the GSH-Ag2Te NPs, a
phantom containing solutions of varying concentrations of silver salt (AgNO3), tellurium
salt (Na2TeO3), iodine (iopamidol, as a control), and the NPs was used. To better mimic
the imaging parameters in human patients’ abdominal cavities, the CT phantom was
submerged in 21 cm of water.41 In addition, the contrast generation of these samples
was evaluated under several of the x-ray energies (80, 100, 120, and 140 kV) most
commonly used in the clinics. A representative image of the different samples acquired
using 80 kV is presented in Figure 3-3A. Quantification of the attenuation rate of the
samples is presented in Figure 3-3B. We found a high attenuation rate for the GSHAg2Te samples, higher than that of silver and tellurium salts. The attenuation rate of the
GSH-Ag2Te NPs is comparable to that of iopamidol, a commonly used CT contrast agent
in clinics, and higher at some energies. This data is in agreement with our previous
publication, where we observed a higher contrast generation of mPEG 5k coated Ag2Te
NP than the silver and tellurium salts as well as iopamidol.22 These results highlight the
potential use of Ag2Te NPs as x-ray imaging contrast agents. Moreover, while the x-ray
attenuation rate of these NPs is lower than that of other materials such as gold and
lanthanide-based NPs, we predict that the contrast generation of GSH-Ag2Te NPs can
be significantly higher in other x-ray imaging modalities such as dual-energy CT and
dual-energy mammography (DEM).22,

28, 42, 43
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Both of these x-ray imaging techniques

could benefit from the K-edges of Ag and Te as they utilize lower x-ray energies than
those employed by conventional CT.

Figure 3-4: In vitro CT imaging. A) Representative CT images of AgNO3 (Ag), Na2TeO3
(Te), Iopamidol (I), and sub-5 nm GSH-coated Ag2Te NPs solutions at different
concentrations (ranging from 0 - 10 mg/mL) at an x-ray tube voltage of 80 kV. B)
Quantification of the CT attenuation rate for the different solutions at varying x-ray tube
voltages. Data is presented as mean ± SD. * p < 0.05.

3.4.4 In vivo imaging shows renal clearance within 2 hours post-injection
An important parameter in the advancement of clinical translation is the ability of
nanoparticles to be sufficiently eliminated from the body in a “reasonable” amount of
time, as stated by the FDA.11 To test whether the GSH-Ag2Te NPs met this requirement,
tail vein injections were carried out in female nude mice at a dose of 250 mg of Ag per
kg of body weight. CT scans were obtained pre-injection and at 5-, 30-, 60-, and 120109

minutes post-injection. Representative 3D reconstruction images of a mouse are
presented in Figure 3-5A. As can be seen, shortly after injection (5 minutes), we
observed high contrast in the kidneys, as shown by the detailed kidney structures
observed in the images (yellow arrow and magnified inset), and the start of their
accumulation in the bladder (yellow dashed circle). As time progressed, we observed a
decrease in the NP accumulation in the kidneys and higher accumulation in the bladder.
At 60 minutes, we observed a much lower contrast in the bladder since the mouse had
recently urinated, clearing most of the NPs. Additional contrast was observed in the
bladder at 120 minutes as the nanoparticles remaining in the mouse were transported
into the bladder to be eliminated. The change in attenuation (HU), from the pre-injection
images, at the different time points in several organs of the mice was quantified and is
shown in Figure 3-5B. This data shows the highest change in attenuation in the bladder
with a decrease in attenuation over time. This data supports the renal clearance of the
GSH-Ag2Te NPs over time.
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Figure 3-5: In vivo CT imaging.A) Representative 3D CT image reconstructions of 3 nm
GSH-coated Ag2Te NPs injected mice at pre-, 5 min, 30 min, 60 min, and 120 min postinjection. Window width (WW): 630 HU and window level (WL): 680 HU. Inset: 3D
reconstruction magnification in the kidney region. WW: 429 HU and WL: 537 HU. B)
Quantification of the CT attenuation in the different organs of mice injected with GSHAg2Te NPs at different time points (5 min, 30 min, 60 min, 120 min post-injection). n=5
per group. Data presented as mean ± SEM. **** p <0.0001.
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We developed GSH-Ag2Te NPs of slightly larger core size (4 nm) to examine the
renal clearance threshold of this type of nanoparticle. The synthesis and characterization
of these nanoparticles are shown in Figure 3-6A-C. As shown in Figure 3-6D-E, these
nanoparticles caused high CT contrast in the liver and spleen, whereas very little
contrast was observed in the kidneys or bladder. These results highlight how a slight
increase in the nanoparticle hydrodynamic diameter can increase nanoparticle retention
in the MPS organs, as seen in previous reports.11
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Figure 3-6: Characterization and in vivo imaging of 4 nm GSH-Ag2Te NPs. A)
Nanoparticle synthesis schematic. B) UV-vis spectrum and C) TEM micrograph of
control GSH-coated Ag2Te NPs. Inset shows the core size and hydrodynamic diameter
(HD) data for control GSH-coated Ag2Te NPs. D) Representative CT images and E)
quantification of the CT attenuation in the different organs of mice injected with 4 nm
GSH-coated Ag2Te NPs injected at different time points (pre-injection, 30 min, 60 min,
and 24 hours post-injection). n=5 per group. Data is presented as mean ± SEM.
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3.4.5 Biodistribution shows clearance of 93% ID in 24 hours
Given the data obtained in the previous section, we further investigated the longterm biodistribution of the nanoparticles after in vivo administration. For this, groups of
mice were injected with the GSH-Ag2Te NPs, euthanized at 24 hours, 7 days, or 28 days
post-injection, and their organs were collected for analysis. Figure 3-7A shows the %ID
accumulated in the different organs at the studied time points. Figure 3-7B shows the
nanoparticle accumulation in other tissues, including the mice carcass. Together this
data shows about 7% ID NP accumulation in main organs, thus suggesting a 93% ID
clearance from these organs in 24 hours. To our knowledge, this is markedly the highest
renal clearance reported in 24 hours for this type of particles and one of the highest
renal clearance rates overall for nanoparticles.14,

44

At 7 days post-injection, 95% ID

clearance from the main organs was observed with a significant decrease in the
nanoparticle accumulation in organs such as the spleen and kidneys compared to 24
hours. Furthermore, 97.5% ID was cleared at 28 days post-injection with a significant
decrease in the nanoparticle accumulation in the liver and spleen compared to 7 days
post-injection. Thus, these results suggest further significant clearance when comparing
the already low nanoparticle accumulation at 24 hours post-injection and that at 28 days.
This high clearance could, thus, improve the chances of clinical translation for GSHAg2Te NPs.
In addition to biodistribution, the mice urine was collected, and TEM micrographs
of the nanoparticles in the urine were analyzed. Figure 3-7C shows a representative
photograph of the urine collected pre-injection where a typical yellow color is observed in
the inset, and no nanoparticles were observed in TEM micrographs. Figure 3-7D shows
114

a representative TEM micrograph of mice urine collected 1-hour post-injection and a
photograph of the urine in the inset. From the photograph, we observed dark-colored
urine, where this color closely matches the GSH-Ag2Te NP solution. The average core
size of the NPs observed in TEM from the urine at 1-hour post-injection was 2.6 nm (±
0.9 nm) which is not significantly different from the core size of GSH-Ag2Te NPs before
injection (3 ± 1 nm). Moreover, the urine collected 24 hours post-injection exhibited a
yellow color close to that of pre-injection, as observed in the inset of Figure 3-7E. The
representative TEM micrograph in Figure 3-7E shows a few scattered NPs. It is worth
noting that very few NPs were observed at this time point. In addition, as with the 1-hour
post-injection, the core size of the NPs observed at 24 hours (3.2 ± 0.7 nm) is not
significantly different from the NPs before injection (3.1 ± 1.3 nm). The core sizes of the
NPs at different time points are summarized in the table in Figure 3-7F. Together this
data suggests the intact excretion of the NP core.
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Figure 3-7: Biodistribution and post-injection urine TEM. Biodistribution at different times
post-injection of sub-5 nm GSH-coated Ag2Te NPs in A) main organs and B) carcass.
n=5 per group. Data is presented as mean %ID ± standard error of mean (SEM).
Representative TEM micrograph of urine collected from mice injected with sub-5 nm
GSH-coated Ag2Te NPs C) pre-injection, D) 60 minutes post-injection, E) 24 hours postinjection. F) Table showing the average core size of nanoparticle micrographs in C), D),
and E) Inset: photograph of representative urine collected at the described time point.
The scale bar represents 20 nm.

3.4.6 No evident toxicity was observed in the mice after GSH-Ag2Te administration
To further evaluate the long-term in vivo biocompatibility of the 3 nm GSH-Ag2Te
NPs, mice weight was recorded over time, in addition to performing histological analyses
and blood chemistry toxicological assays. Figure 3-8A shows the weight of control mice
(uninjected) and mice injected with GSH-Ag2Te over 28 days. As shown in this figure, no
significant difference in the weight of the two mice groups was observed. Moreover, no
additional differences were observed in the mice's physical characteristics or behavior
between the groups over the 28-day study period. Blood was collected at 24 hours, 7
days, and 28 days post-injection for serum chemistry toxicology. The results from the
toxicology panel are presented in Figure 3-8B-D. While some results from 28 days postinjection are higher due to a high level of hemolysis in the sample collection and could
benefit from repeating the experiment to confirm the results further, these results show
no statistically significant difference in the studied enzymes and markers levels in the
serum of mice injected with GSH-Ag2Te at the various time points post-injection
compared to control. Thus, suggesting no significant changes in the mice's normal liver
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and kidney function at the various times post-injection compared to the control mice. For
histological analysis, tissue from the main organs (i.e., heart, liver, spleen, kidneys, and
lungs) was collected from mice at 24 hours, 7 days, and 28 days post-injection. This
tissue was then subjected to hematoxylin & eosin (H&E) staining. Mice injected with
saline were used as controls. Figure 3-6E shows representative tissue slides from mice
injected with saline or GSH-Ag2Te NPs at 1 day, 7 days, and 28 days post-injection.
From this data, we observed no evident changes in the tissues of mice injected with
GSH-Ag2Te at different time points when compared to the control tissue. Together the
histology and serum chemistry panels suggest that no signs of toxicity were further
observed in the mice even after longer-term exposure (28 days) to the nanoparticles.
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Figure 3-8: In vivo toxicology. A) Body weight of control mice (uninjected) and GSHAg2Te treated mice over 28 days. B-D) Serum chemistry panels of mice injected with
either PBS or GSH-Ag2Te at different times post-injection. Serum levels of B) alkaline
phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase
(AST), C) blood urea nitrogen (BUN), and D) total bilirubin and creatinine in the different
mice groups. Data presented as mean ± SEM. E) Representative histology (H&E
staining) micrographs of mice organs after injection with either PBS or GSH-coated
Ag2Te NPs at different times post-injection. Scale bar = 50 µm.

3.5 Discussion
We have developed an aqueous synthesis yielding 3 nm Ag2Te NPs using GSH
as the coating. This small core size of the GSH-Ag2Te NPs allows for their rapid
excretion. In addition, the biocompatibility of the GSH-Ag2Te NPs is very good and is
comparable to that of larger PEG-coated Ag2Te NPs previously developed by our group
and other sub- 5 nm silver chalcogenide NPs.12,

22

Their biocompatibility, even at high

concentrations, speaks to the potential application of the NPs in different biomedical
areas. Moreover, we herein report a renal clearance efficiency value (93% ID)
comparable to the highest 24 hours clearance rate reported to date (95% ID) for any
type of nanoparticle.26 This clearance is also the highest reported for Ag2Te and other
Ag2X NPs (~85% ID) at 24 hours post-injection.12, 25, 26 The renal clearance at 24 hours
post-injection for most nanoparticles is only around 50% ID.14 While other Ag2Te NPs
have been developed to achieve renal clearance, they report a clearance value of ~25%
ID/g albeit at a much lower dose (>100 times lower).25 Previous studies have reported a
higher clearance rate in particles injected at a lower dose, further emphasizing the
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significance of the nanoparticles presented herein and their clearance.45 Other Ag2X NPs
have been developed to achieve renal clearance.12, 46 Examples include those reported
by Ge et al. and Hsu et al., where Ag2Se and Ag2S nanoparticles were developed with
core sizes of 2 and 3 nm, respectively.12, 46 Both studies reported a renal clearance of
~85% ID.12, 46 Moreover, the rapid renal excretion (93% ID in 24 hours) reported herein
led to less NP accumulation in the body over time, as shown in our long term
biodistribution study where only 4.8 %ID remained in main organs of the mice after 7
days of injection and 2.5 %ID after 28 days. This low NP accumulation could lead to a
better safety profile and could thus, facilitate its clinical translation process. This efficient
renal clearance, being among the highest reported to date, and their strong evidence of
biocompatibility, even at the high concentrations used, can facilitate their clinical
translation for their use as x-ray contrast agents and in many other biomedical
applications (e.g., photothermal therapy, photoacoustic imaging, and near-infrared
fluorescence imaging).
While the biocompatibility and renal clearance of the GSH-Ag2Te NPs met our
experimental goals, the CT contrast generated by these NPs was slightly lower than that
previously reported by our group.22 We hypothesize that this lower contrast observed in
3 nm Ag2Te NPs compared to the larger NPs, is due to the incorporation of fewer
tellurium atoms in the NP cores, as shown by the higher ratio of Ag to Te in the EDX
data in Figure 3-1D. This could be due to the larger surface area characteristic of
smaller nanoparticles with more sites being occupied by the sulfur atoms in the capping
agents at the surface as opposed to Te.47,

48

Future experiments could include

optimizing the ratio of Ag to Te to further increase the contrast generated by these NPs.
Furthermore, we predict that the contrast generation of GSH-Ag2Te NPs can be
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significantly higher in other x-ray imaging modalities such as dual-energy CT and DEM,
as shown in our previous study.22 Both dual-energy CT and DEM utilize much lower xray energies than that of conventional CT, which more closely aligns with the K-edge of
Ag and Te. In the case of DEM, a lack of contrast agents specifically designed for this
imaging technique currently exists, leading clinics to rely on iodinated contrast agents,
which don’t have optimal contrast and could cause adverse reactions to some patients.
Thus, the high contrast generation of GSH-Ag2Te, along with its biocompatibility and
rapid excretion, can lead to their application as DEM-specific contrast agents for breast
cancer screening.
While the data presented in this study is promising for the further use of GSHAg2Te NPs in different biomedical applications and their subsequent clinical translation,
we recognize some of the limitations of this study. For example, the biocompatibility
studied here is limited to the cell lines and mouse models used. A broader assessment
of their biocompatibility and in vivo toxicology would be desired for further clinical
translation. Moreover, our future experiments include exploring the imaging properties of
these nanoparticles in a mouse tumor model, especially using DEM or dual-energy CT.
In addition, we will explore different ligands as capping agents for the Ag2Te NPs and
test whether they could lead to higher clearance while achieving high NP accumulation
in the tumor site. This would be particularly beneficial for the use of renally clearable
Ag2Te NPs as a contrast agent for cancer detection.

3.6 Conclusion
We have developed an aqueous synthesis and extensively characterized the
resulting 3 nm GSH-coated Ag2Te NPs. These NPs have the potential to be used as an
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x-ray contrast agent. Their contrast generation in CT was comparable to, if not higher
than, commercially available iodinated contrast agents. In addition, GSH-Ag2Te NPs
were shown to be biocompatible with kidney and liver cell lines showing no effect on the
cell viability and low ROS generation after 4 hours of incubation. The GSH-Ag2Te NPs
showed high contrast in the kidneys and bladder rapidly after injection (i.e., 5 minutes
post-injection). This contrast decreased over time as the particles were cleared through
the urine over 2 hours post-injection. Moreover, our biodistribution results suggest
around 93% ID clearance from main organs after 24 hours of injection, 95% ID after 7
days, and 97% ID after 28 days. These clearance rates are, to our knowledge, the
highest reported to date for Ag2Te NPs and among the best for any nanoparticle type.
Moreover, the high dose of nanoparticles used in this study (250 mg/kg) can highlight
their potential use in other biomedical applications. Together, the excellent
biocompatibility and efficient renal clearance of GSH-Ag2Te NPs show their potential to
be used as an x-ray contrast agent amongst other applications with good prospect for
clinical translation.
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3.8 Supplemental Figures

Supplemental Table 3-1: Reactions for the synthesis of sub 5 nm Ag2Te nanoparticles.

Coating

GSH
30mM

GSH
60 mM

Reaction
time

Temp.

Core size
(nm)

Hydrodynamic
diameter (nm)

10 min

RT

4±1

4±4

12 min

RT

3.6 ± 0.9

5±1

13 min

RT

4±1

1.3 ± 0.7

15 min

RT

4±1

4.4 ± 0.6

Overnight

RT

5±1

10 ± 1

5 min

Ice

3±1

4.5 ± 0.1

10 min

Ice

4±1

Undetectable

15 min

RT

2±1

8±3

127

3-MPA
30 mM

3-MPA
90 mM

10 min

RT

3±2

11 ± 4

12 min

RT

5.5 ± 0.7

9±5

13 min

RT

4±1

11 ± 2

15 min

RT

7±2

11.71 ± 0.02 nm

15 min

Ice

2.1 ± 0.7

2±1

10 min

Ice

4±1

14 ± 1

5 min

Ice

3±1

Undetectable

15 min

RT

2±1

16 ± 6

15 min

Ice

1.8 ± 0.7

Undetectable

10 min

Ice

8±1

3±3
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Chapter 4: Ultra-small MoS2 nanoparticles as contrast agents for
dual-energy mammography and computed tomography

4.1 Abstract
Molybdenum disulfide nanoparticles (MoS2 NPs) have been shown to attenuate
x-rays due to molybdenum’s relatively high atomic number, while having good
biocompatibility. However, reports studying their use as x-ray contrast agents have been
few. In this work, we have developed a novel aqueous synthesis yielding 2 nm MoS2
with zwitterionic coatings, including glutathione (GSH), L-cysteine, and penicillamine.
These particles were shown to have low in vitro cell toxicity when tested with various cell
lines at concentrations up to 1 mg/mL, the highest concentration studied. Moreover, for
the first time, these particles were shown to generate clinically relevant contrast in DEM,
a recently approved mammography technology specially designed for breast cancer
screening in women with dense breasts. In DEM, MoS2 NPs generated higher contrast
than iopamidol, a commercially available x-ray contrast agent, while generating
substantial contrast in CT. Together, the presented data highlight the potential use of
MoS2 NPs as a safe and effective x-ray and DEM-specific contrast agent.

4.2 Introduction
Molybdenum disulfide nanoparticles (MoS2 NPs) belong to the transition metal
dichalcogenide (TMD) family. TMDs are materials with the chemical composition, MX2,
where M represents the transition metal ion and X the chalcogen ions (S, Te, Se).1
MoS2, along with other TMDs, are considered graphene-analogs with unique structure
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and photoelectric properties as well as high cytocompatibility.2,

3

Therefore, they have

recently gained attention in a wide range of biomedical applications.3,

4

Among their

different biomedical applications, TMDs have been shown to produce x-ray contrast due
to the transition metal’s relatively high atomic number.1, 5-7 Yet, the use of MoS2 NPs and
other TMDs, as x-ray contrast agents, has been limited.8
In addition to their contrast generation in computed tomography (CT), a widely
used x-ray imaging modality, molybdenum can produce strong contrast in dual-energy
mammography (DEM).9 DEM is a type of mammography recently approved by the Food
and Drug Administration to detect breast cancer in women with dense breasts.10 Breast
density is defined as the ratio of fibroglandular to adipose tissue and can markedly affect
the ability of conventional mammography to detect breast cancer.11 Therefore, DEM is
considered a highly promising breast imaging technique for women with dense breasts,
which make up to 50% of the female population in the US.12 However, DEM requires the
administration of a contrast agent. While efforts have been made for the development of
DEM-specific contrast agents, at this moment, there are none commercially available.1315

Therefore, clinics need to rely on iodine-based contrast agents which have not been

optimized for this technique.9

Thus, a need for the development of DEM-specific

contrast agents currently exists and led us to explore MoS2 NP for this purpose.
For the successful translation of MoS2 NPs as x-ray contrast agents, it is
important to determine not only their high contrast and biocompatibility but also their
ability to be rapidly eliminated from the body.16-18 Rapid elimination of NPs can help
avoid any further potential toxicity concerns.19 Renally excretable nanoparticles are
designed to meet this rapid excretion due to their small size (sub 5 nm) and zwitterionic
coatings, which allows their filtration through the kidneys’ glomerulus and avoids uptake
by the monocyte-phagocytic system.18, 20
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In this study, we have developed a unique aqueous synthesis for MoS2 NPs with
a core diameter of 2 nm and explored the NPs in vitro biocompatibility and x-ray contrast
generation in DEM and CT. Moreover, we sought to determine whether the nanoparticle
coating affected their biocompatibility and renal excretion. For this, we synthesized and
characterized a group of 2 nm MoS2 NPs with different zwitterionic small compounds
previously used to develop sub – 5 nm NPs such as glutathione, penicillamine, and
cysteine, as their coatings.18,

21-25

We then evaluated their biocompatibility, in vivo CT

contrast, and renal clearance. To the best of our knowledge, this is the first study using
this synthetic approach to develop MoS2 NPs and exploring their use as x-ray contrast
agents at the mg/kg of body weight dose range and more specifically, as dual-modality
x-ray contrast agents for DEM and CT.

4.3 Materials and Methods
4.3.1 Materials
Sodium molybdate dihydrate (Na2MoO4), L-cysteine, 3-mercaptopropionic acid
(3-MPA), L-glutathione reduced (GSH), D-penicillamine, and sodium sulfide were
purchased from Sigma-Aldrich (St. Louis, MO). Nitric acid (HNO3) was purchased from
Fisher Chemical (Thermo Fisher, Waltham, MA). Milli-Q deionized water (18.2 MΩ cm)
was used throughout the experiments.

4.3.2 MoS2 NP synthesis and purification
To synthesize 2 nm MoS2 NPs, different concentrations of the various coatings
tested (e.g., GSH, penicillamine, 3-MPA, and L-cysteine), as described in Supplemental
Table 1, were dissolved in 7 mL of DI water. Next, 1 mL of a sodium molybdate aqueous
131

solution (10.88 mg/mL) and 1 mL of sodium sulfide aqueous solution (7.1 mg/mL) were
added. The reaction was allowed to proceed at room temperature for 10 minutes. 0.5 – 1
kDa dialysis tubing was used to purify the MoS2 NPs overnight. 3 kDa molecular weight
cut-off tubes were used to concentrate the GSH-MoS2 NPs by centrifugation at 4,000
rpm. The particles were concentrated to 1 mL, filtered using 20 nm filters, and then
stored at 4 °C until further use. The penicillamine- and cysteine-coated MoS2 NPs were
filtered with a 20 nm filter following dialysis. To concentrate these, the nanoparticles
were lyophilized for 5 days, resuspended in 1 mL of DI water, and stored at 4 °C until
further use.

4.3.3 Nanoparticle characterization
4.3.3.1 Transmission electron microscopy (TEM) micrographs
TEM micrographs were obtained as described elsewhere.15 In brief, 10 µL of a
sample concentrated to 0.5 mg/mL were dried into a carbon-coated copper grid with 200
mesh. The grids were purchased from Electron Microscopy Sciences (Hatfield, PA). The
samples were imaged using a Tecnai T12 electron microscope operated at 100 kV to
measure the nanoparticle core size. The core diameter was measured using ImageJ
(National Institutes of Health, Bethesda, MA).
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4.3.3.2 UV-vis spectroscopy
UV-vis spectra of the MoS2 NPs were recorded using a Genesys 150 UV/Vis
spectrophotometer purchased from Thermo Scientific, USA. The samples were prepared
by diluting 5 µL of the concentrated samples in 995 µL of DI water.

4.3.3.3 Z-potential measurements
Z-potential measurements of the MoS2 NPs were acquired using a Zetasizer
Nano from Malvern Instruments. The samples were prepared by diluting 5 µL of
concentrated MoS2 NPs were diluted in 995 µL of DI water. The sample was then
transferred into a folded capillary cell for the z-potential measurement.

4.3.3.4 Fourier transformation infrared spectrometry (FT-IR)
FT-IR samples were prepared by combining 100 mg of KBr with 5 mg of the
MoS2 NPs. The samples were then dried in an oven, and a pellet press was used to form
the KBr pellets. The FT-IR spectra were obtained using a Jasco FT/IR 480 plus
spectrometer.

4.3.3.5 X-ray powder diffraction (XRD)
XRD samples were prepared by drying 400 µL of the concentrated MoS2 NPs on
a silicone disk. The diffraction patterns of the samples were obtained using a Rigatu
MiniFlex x-ray diffractometer. The diffractometer was operated at an x-ray energy of 45
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kV, a current of 30 mA, and 1.5406° Cu Kα radiation wavelength. The scans were
performed using a scan rate of 2° per minute and 20-60° scan range.

4.3.3.6 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES)
ICP samples were prepared by digesting 10 µl of the concentrated MoS2 NP
solution in 500 µL of nitric acid for at least 1 hour. Next, 9.49 mL of DI water were added
to each sample. A Spectro Genesis ICP-OES was used to measure the molybdenum
concentration in each sample.

4.3.4 In vitro biocompatibility assay
4.3.4.1 Cell culture
HepG2 (liver), J774A.1 (macrophage), and MDA-MB-231 (breast cancer) cell
lines were cultured following the ATCC recommendations. In brief, 5% CO 2 and a
temperature of 37 °C were used to incubate the cells. The cell media recommended for
each cell line were supplemented with 10% fetal bovine serum (FBS) (Corning,
Tewksbury, MA) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Waltham,
MA).

4.3.4.2 LIVE/DEAD staining
LIVE/DEAD staining was performed as described elsewhere.15 In brief, 24 hours
before the experiment, cells were plated at a density of 80,000 cells in a 35 mm round
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bottom flask and kept in cell media. The next day, the cells were treated with MoS2 NPs
at concentrations ranging from 0 to 1 mg/mL for 4 hours. Then, the cells were washed
with PBS and incubated with 400 µL of a staining solution for 20 minutes. The staining
solution contains Calcein AM, Ethidium-1 homodimer, and Hoechst 33342 for live cells,
dead cells, and nucleus staining, respectively. Next, the cells were imaged using a Zeiss
Axiovert fluorescence microscope equipped with FITC, Texas Red, and DAPI filters. In
each plate, we acquired 4 images per filter. The percentage of live cells compared to
dead cells was determined using FIJI (ImageJ). The data was normalized to the control
and is presented as % of control.

4.3.5 Phantom imaging
4.3.5.1 DEM phantom imaging
DEM phantom imaging was performed as described elsewhere.15 In brief, PBS,
iopamidol (10 mg/mL) and GSH-MoS2 NP solutions of varying concentrations (0 – 10
mg/mL) were loaded into polyethylene tubes. These tubes were then inserted into a
custom-designed phantom composed of tissue-equivalent materials mimicking breast
tissue in a range from 100% glandular tissue to 100% adipose tissue. Images of the
phantom were acquired, in triplicate, using a DE Hologic Selenia Dimensions
mammography system at low energy (LE) of 23 kV and high energy (HE) of 32 kV. DE
images of the phantoms were obtained by a weighted logarithmic subtraction of the HE
and LE image pairs.
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4.3.5.2 CT phantom imaging
CT phantom images were acquired as described elsewhere.15 In brief, triplicate
solutions of varying concentrations (0 – 10 mg of the element of interest /mL) of GSHMoS2, Na2MoO4, and iopamidol as a positive control were prepared in 300 µL tubes.
Tubes with PBS were imaged as a negative control. The tubes were placed in a plastic
rack, covered with parafilm, and submerged in 21 cm of water to simulate the average
human body thickness. CT images were acquired using a Siemens SOMATOM Force
clinical CT scanner using the following parameters: tube voltages of 80, 100, 120, and
140 kV, 360 mAs tube current, 37 x 37 cm field of view, 0.5 mm thickness, and a 512 x
512 matrix. CT images were analyzed by drawing a region of interest (ROI) in the tubes
using OsirixMD software and recording their CT attenuation. The data is presented as
the average of three slices per tube.

4.3.6 Statistical analysis
In this study, all experiments were performed at least three times independently.
One-way ANOVA was used to compare the data in the DEM phantom study. Multiple ttest (Welch test) was used to compare the data in the cell viability and CT phantom
study. In all figures, data is presented as the mean value ± standard deviation (SD) or
standard error of the mean (SEM), as specified on each figure legend. Statistical
analysis was performed using Prism Graphpad 9 (San Diego, California USA) where p
values < 0.5 were considered statistically significant.
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4.4 Results
4.4.1 Synthesis and characterization of GSH- and penicillamine-coated MoS2 NPs
The challenge of synthesizing renally excretable MoS2 NPs was developing NPs
below the renal clearance size threshold of 5.5 nm, with zwitterionic coatings to avoid
serum protein adsorption and provide colloidal stability. To synthesize MoS2 NPs with
these characteristics, we tested different synthetic methods, reaction conditions, and
coatings, as presented in Supplemental Table 1. We characterized the library of MoS2
NPs and selected those that met the size and colloidal stability requirement to further
advance their exploration as renally excretable x-ray contrast agents. A schematic of the
syntheses leading to the formulations that met the previously described requirements
are presented in Figure 4-1A. TEM micrographs of these GSH- and penicillaminecoated MoS2 NPs are presented in Figure 4-1B-C and show their 2 nm average core
size. The z-potential shown in Figure 4-1D confirms the successful incorporation of the
different coatings into the NPs. These values are in agreement with other reports where
GSH and penicillamine coatings provide a neutral to slightly negative surface charge.26-28
A UV-vis spectrum for each sample, showing the characteristic peak of MoS2 NPs at 215
nm, is presented in Figure 4-1E.29 To further confirm the incorporation of the different
coatings, FT-IR was performed, and the spectra are presented in Figure 4-1F. From this
data, we observe the 3300 cm-1 band (-NH stretching) and 1650 cm-1 peak (-COOH)
characteristic of GSH and 3400 cm-1 (O-H stretch), 1650 cm-1 (-COOH), and 2950 cm-1
(C-H) peak characteristic of penicillamine, respectively.30,
weak peaks at 465 cm

-1

31

In addition, we observe

in both samples, characteristic of Mo-S vibrations.32,

33

Moreover, the lack of the characteristic thiol band at 2500cm-1 suggests the successful
incorporation of the coatings to the NP surface.
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Figure 4-1: Synthesis and characterization of GSH- and penicillamine-coated MoS2 NPs.
A) Schematic representing the aqueous synthesis of MoS2 NPs with the different
capping agents. Transmission electron micrographs of B) GSH and C) penicillaminecoated MoS2 NPs. Scale bar = 20 nm. D) Z-potential, E) UV-vis spectra, and F) FT-IR
spectra of MoS2 with different coatings. Z-potential data is presented as mean ±
standard deviation.
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An important predictor of in vivo behavior of the MoS2 NPs is their stability in PBS
supplemented with 10% FBS. To test the MoS2 NP stability, we incubated the different
types of particles in water, PBS, and PBS with FBS and recorded their UV-vis spectra
over time. An unchanged spectrum represents stable NPs. The data for each NP type
over time is presented in Figure 4-2. The figure shows that GSH- (Figure 4-2A-C) and
penicillamine-coated MoS2 NPs (Figure 4-2D-F) are stable for at least 48 hours. The
experiment was conducted for 2 days based on the rapid in vivo renal clearance
expected with these types of NPs.
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Figure 4-2: Stability of MoS2 NPs in different media.Stability of GSH-coated MoS2 NPs in
A) water, B) PBS, and C) PBS + 10% FBS over 48 hours. Stability of Penicillaminecoated MoS2 NPs in D) water, E) PBS, and F) PBS + 10% FBS over 48 hours.

4.4.2 MoS2 nanoparticles do not affect the viability of cells in vitro
To further predict the in vivo biocompatibility of these NPs, we tested their in vitro
biocompatibility with some of the cell types where we would expect these NPs to interact
in vivo. Figure 4-3 shows the cell viability of J77A4.1 (macrophage), HepG2 (liver), and
MDA-MB-231 (breast cancer) cells after 4 hours of incubation with GSH- and
penicillamine-coated MoS2 NPs at concentrations ranging from 0 – 1 mg of Mo per mL.
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These results show the biocompatibility of the different types of MoS2 NPs with the
studied cell lines, even at a high concentration of 1 mg/mL. To the best of our
knowledge, this is the first study testing the biocompatibility of these NPs up to a
concentration of 1 mg/mL.8, 34, 35 This concentration is higher than that required by most
biomedical imaging applications (ng-µg/mL range), suggesting that the biocompatibility
of these NPs can lead to their application in other biomedical applications.36-39

Figure 4-3: Cell viability after incubation with GSH- and penicillamine-coated MoS2 NPs.
Cell viability of J774A.1 (orange), HepG2 (blue), and MDA-MB-231 (green) after
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incubation with A) GSH-MoS2 and B) penicillamine-MoS2 NPs at varying Mo
concentrations. Data is presented as the mean percentage of viability normalized to
control ± SD. n.s. = no statistical significance.

4.4.3 MoS2 nanoparticles generate higher contrast than iopamidol in DEM phantom and
substantial contrast in CT phantom
As previously discussed, molybdenum has been identified as a material with high
contrast generation in DEM.9 To test whether the 2 nm MoS2 NPs generated contrast, as
expected from the initial studies, we used a DEM phantom. This phantom is composed
of tissue-mimicking materials which closely resemble a range from 100% glandular
tissue to 100% adipose tissue in DEM. By inserting a sample in the phantom, we can
evaluate its contrast at the different breast density levels. Figure 4-4A shows a
representative image of PBS, iodine control in the form of iopamidol at a concentration of
10 mg of iodine/mL, and GSH-MoS2 NPs at different concentrations. For this image, the
energies were set at 23 kV and 32 kV for the LE and HE, respectively. The DE
subtraction image highlights the uniform contrast observed regardless of the density
level in the phantom. Of note, we tested the contrast in only one of the formulations
since we do not expect the coating to affect the contrast generation of the NPs. Figure
4-4B shows the contrast-to-noise ratio (CNR) quantification at the mentioned energy
pair. This data shows higher CNR, at the studied energy pair, for GSH- MoS2 NPs than
iopamidol, a clinically used x-ray contrast agent, at 10 mg of the element of interest/mL.
To the best of our knowledge, this is the first report showing the use of MoS2 NPs as
DEM contrast agents.
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We further evaluated the x-ray contrast generation of the MoS2 NPs by using a
CT phantom designed to mimic the abdominal cavity of human patients. In this phantom,
iodine (in the form of iopamidol), Na2MoO4, and GSH-MoS2 NPs samples at
concentrations ranging from 0 – 10 mg of the element of interest were submerged in 21
cm of water. PBS samples were used as a negative control. We obtained images at
clinically relevant x-ray energies of 80, 100, 120, and 140 kV. Representative images of
the different samples, obtained at 80 kV, are presented in Figure 4-4C. Figure 4-4D
shows the attenuation rate quantification of the different samples and shows that, while
less contrast is obtained compared to iopamidol, MoS2 NPs can generate substantial
contrast in CT. This data highlights the contrast generation of MoS2 NPs in the different
x-ray imaging modalities. Moreover, highlights its potential use as DEM and CT contrast
agents.
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Figure 4-4: DEM and CT phantom imaging. A) Representative images of PBS, iodine (10
mg/mL) in the form of iopamidol, and solutions containing NPs at varying Mo
concentrations (1-10 mg/mL). Images were acquired at a LE= 23 kV and HE = 32 kV
using a custom-designed DEM phantom. B) Quantification of the contrast-to-noise ratio
(CNR) of the solutions described in panel A. Data is presented as mean CNR ± SD. C)
Representative CT phantom images of solutions containing NPs at varying
concentrations, a Mo precursor (Na2MoO4), iodine in the form of Iopamidol, and PBS.
These representative images were acquired at an x-ray energy of 80 kV. D)
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Quantification of the attenuation rate from the solutions described in panel C, at varying
x-ray energies. Data is presented as mean ± SD. **** p < 0.0001. * p < 0.05. n.s. = not
statistically significant.

4.5 Discussion
Among the numerous biomedical applications where MoS2 NPs can be
beneficial, they have not been widely explored in x-ray imaging. To this date, only 2
other studies have been published exploring the use of MoS2 NPs as a CT contrast
agent, although at very low doses.8,

35

In the work described by Wang et al., MoS2

nanohybrids composed of MoS2 quantum dots and polyaniline were injected at a low
dose (200 µL, 8 mg/mL) into breast cancer tumor bearing-mice via tail-vein to evaluate
their in vivo CT contrast. This study showed an average change in attenuation of 108.7
HU 8 hours post-injection. However, although the quantification was not presented, CT
images reveal a high accumulation of the nanohybrids in the liver at 8 hours postinjection. In the work described by Li et al., MoS2 quantum dots were loaded into silica
oxide nanoparticles as multimodal agents where a low dose of the nanoparticles (2
mg/mL, 200 μL) was administered to mice to test their in vivo CT contrast. They report
maximum contrast at 12 hours post-injection with an average change in attenuation of
105.9 HU. Biodistribution experiments showed high nanoparticle accumulation in the
liver and spleen of the mice. The low doses used in these studies, while relevant to
other imaging and therapeutic applications, including fluorescence and photoacoustic
imaging and photothermal therapy, are lower than those used in clinical CT imaging.
Thus, these studies do not necessarily reflect the CT imaging capabilities of MoS2 or
their safety in a clinical setting. Moreover, the overall large size of the nanoparticles
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reported in these studies leads to their accumulation in the liver and spleen resulting in
potential long-term toxicity concerns.
In this work, we developed a novel aqueous synthesis leading to a library of 2 nm
MoS2 NP with different coatings. Among these, we further characterized those that met
the size and long-term stability requirements: GSH- and penicillamine-coated MoS2 NPs.
Both types of particles have excellent biocompatibility with the studied cell lines, even at
high concentrations tested. As described above, to the best of our knowledge, this is the
first study measuring the biocompatibility of these particles at concentrations in the
mg/mL range. Moreover, we were able to confirm, for the first time, that MoS2 NPs
produce high contrast in DEM. GSH-MoS2 NPs, at an optimal energy pair of 23 kV (LE)
and 32 kV (HE), show higher contrast in vitro DEM than the commercially available
iopamidol x-ray contrast agent while also showing substantial contrast in CT. Together,
the results highlight the biocompatibility, stability, and x-ray contrast generation of MoS2
NPs. Thus, presenting a new potential application for MoS2 NPs.
While the results herein presented highlight the benefits of MoS2 NPs in x-ray
imaging, we acknowledge that there are some limitations to our study. For example, the
biocompatibility results herein presented are limited to the studied cell lines and only
focus on the viability of the cells. Future experiments include investigating the in-depth
biocompatibility of the particles in different cell lines, including DNA damage
quantification and generation of reactive oxygen species. In addition, in vivo studies
(currently ongoing) in breast cancer tumor models, evaluating their long-term
biocompatibility should be tested to predict clinical translation better. Furthermore, the
studies herein presented focus on the application of MoS2 NP as x-ray contrast agents
and do not test their properties for their use in other biomedical applications. Future
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experiments include testing their near-infrared fluorescence and thermal generation
properties for their application in fluorescence imaging and photothermal therapy,
respectively.

4.6 Conclusion
In this work, we have developed a novel aqueous synthesis yielding 2 nm GSHand penicillamine-coated MoS2 NPs. The particles are stable in different media for at
least 48 hours. Moreover, neither of the MoS2 NP formulations affected the viability of
the studied cell lines, even after incubation with a high concentration of 1 mg of Mo /mL,
the highest concentration studied to date. Furthermore, we have tested for the first time
the x-ray contrast generation of MoS2 NPs in DEM, a newly FDA-approved
mammography equipment for the detection of breast cancer. MoS2 generated
substantially higher contrast in DEM than iopamidol, the x-ray contrast agent currently
used in the clinics, and high contrast in CT. The results presented in this chapter
highlights the potential use of MoS2 NPs as DEM contrast agents for breast cancer
detection.
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4.8 Supplemental Figures

Supplemental Table 4-1: Synthesis and characterization of MoS2 NPs with different
coatings.

Coating
GSH
53 mM

Reaction
time (min)
24 hrs

Core size
(nm)
200 °C Large
aggregates
150
Temp.

(autoclave)
GSH
60
5 mM (under
argon gas)
GSH
60
5 mM (under
argon gas)
GSH
60
5 mM (under
argon gas)
GSH
30
30 mM
(+ N2H4)
GSH
15
30 mM
(+ N2H4)
GSH
10
30 mM
(+ N2H4)
GSH
10
30 mM
(+ N2H4)
GSH
10
30 mM
GSH
10
30 mM
L-cysteine
10
30 mM
L-cysteine
10
60 mM
L-cysteine
10
90mM
3-MPA
10
38 mM
Penicillamine 10
30 mM
RT: room temperature.

RT

68.0 ± 34.2

90 °C

27.2 ±
134.7

50 °C

17.3 ± 34.6

RT

14.8 ± 23.7

RT

6.8 ± 2.6

90 °C

2.0 ± 0.6

RT

2.9 ± 1.0

90 °C

4.2 ± 1.9

RT

2.2 ± 0.7

RT

Aggregated

RT

5.3 ± 2.4

RT

2.3 ± 0.8

RT

5±1

RT

1.9 ± 0.6
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Chapter 5: Overall discussion and future directions

5.1 Overall discussion
DEM has been recently approved by the FDA for its use in breast cancer
screening in women regardless of breast density. With this advancement in breast
cancer screening technology arises the need for DEM-specific contrast agents. To date,
only our group has centered on developing DEM-specific contrast agents, which have
focused mostly on silver-based nanoparticles.1-4 The work described in this thesis has
further advanced the development of DEM-specific contrast agents by exploring different
materials and their development as nanoparticles. The key findings of each project have
been discussed in previous chapters. This section will further highlight the overall key
findings and the limitations of the studies.
In chapter 2, I developed proof-of-concept Ag2Te nanoparticles and explored
their biocompatibility and contrast in DEM and CT.5 The nanoparticles were developed
through a simple and novel aqueous synthesis using mPEG-SH 5K as a coating yielding
8 nm core sized particles with a 16 nm hydrodynamic diameter. The mPEG-SH 5K
coating used for these particles provided colloidal stability for at least 14 days and
contributed to their prolonged blood circulation and biocompatibility. PEGylation
improves exogenous materials' biocompatibility and circulation time by shielding the
surface from aggregation, opsonization, and phagocytosis.6-10 In addition to PEGylation,
an important inherent property of Ag2Te (Ksp = 2.0 x 10-72) and other silver chalcogenide
nanoparticles (Ksp Ag2S = 6 x 10-50 and Ksp Ag2Se = 3 x 10-65) leading to broad
biocompatibility is their extremely low solubility product. Together, these properties lead
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to biocompatible Ag2Te NPs in vitro with no changes in the viability of the studied cell
lines and in vivo after injection to breast cancer tumor-bearing mice with no observed
acute toxicity in histology slides. Moreover, we studied the contrast generation of Ag2Te
NPs in DEM and CT. While the contrast production of other silver-based nanoparticles
had been studied in DEM, this study was the first to test the contrast generation of Ag2Te
NPs and tellurium’s contribution to the contrast.1, 2, 11, 12 Our results showed higher x-ray
contrast, in both CT and DEM, in Ag2Te NPs compared to silver-based NPs and iodinebased contrast agents. The x-ray contrast generated by Ag2Te NPs was higher than that
expected from adding the contribution of both silver and tellurium metals, which we
hypothesize is due to a phenomenon where nanoparticles composed of multiple
materials generated higher contrast than the individual metals, as reported by Kim et al.
13

Moreover when injected into breast cancer tumor-bearing mice, Ag2Te NPs showed

higher contrast in the tumors as compared to Ag2S nanoparticles of the same size and
coating, further highlighting the contrast contribution of the tellurium atoms. While the
data presented in Chapter 2 on the contrast and biocompatibility of Ag2Te NPs served as
a proof-of-concept for their potential use as a DEM and CT contrast agent for breast
cancer screening, their biodistribution data suggests their accumulation in the liver and
spleen of breast cancer tumor-bearing mice at 24 hours post injection. The NP
accumulation in MPS organs could lead to long term retention of the nanoparticle in
vivo.14,

15

To address this potential safety concern, Chapter 3 focused on developing

renally excretable Ag2Te NPs as x-ray contrast agents.
Renally excretable nanoparticles are designed to have a size below the kidney’s
glomerular filtration size threshold of 5.5 nm and, as a result, have the advantage of
being readily excreted through the urine. In Chapter 3, I designed 3 nm GSH-coated
Ag2Te NPs as renally excretable x-ray contrast agents to further facilitate their clinical
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translation. I developed these 3 nm GSH-Ag2Te NPs through a new and rapid aqueous
synthesis using silver and tellurium precursors in the presence of hydrazine as a
reducing agent and GSH as the coating. GSH, a zwitterionic small molecule, has been
used to coat other renally excretable nanoparticles since it provides stability and
biocompatibility to the nanoparticles while maintaining a small hydrodynamic diameter.3,
16-20

As a result of the GSH coating and the inherent biocompatibility of Ag2Te

nanoparticles previously described, the 3 nm GSH-Ag2Te NPs were biocompatible (no
changes in cell viability or ROS generation as compared from control) with liver and
kidney cells. Another important study for the clinical translation of these NPs is their
long-term in vivo biocompatibility. For this, we injected the GSH-Ag2Te into nude mice
and collected blood and tissue for blood chemistry and histology, respectively, at 1 day,
7 days, and 28 days post-injection. Histology showed no signs of acute toxicity, while
blood chemistry showed no differences in the levels of the studied enzymes at the
different time points compared to PBS-injected mice. In addition, we tested the x-ray
contrast generation of the GSH-Ag2Te NPs in CT, where we observed higher contrast
from the GSH-Ag2Te NPs compared to the individual metal precursors, as expected from
the studies described in Chapter 2, and higher or equal contrast than iopamidol, a
commercially available x-ray contrast agent. We also tested the in vivo contrast in CT by
injecting the GSH-Ag2Te NPs into nude mice and comparing the images acquired at 5-,
30-, 60-, and 120- minutes post-injection to pre-injection scans. This study further
confirmed the high contrast generation of the nanoparticles and, most importantly, their
successful renal excretion as observed by the rapid (5 min post-injection) contrast
observed in the kidneys and bladder. Moreover, we tested the long-term biodistribution
of the GSH-Ag2Te NPs at 1 day, 7 days, and 28 days post-injection, where we found a
total clearance from main organs of 93%, 95%, and 97%, respectively. These data
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represent the highest clearance for Ag2Te NPs reported to date and among the highest
for all nanoparticle types.4, 17, 21-24 Together, the results presented in Chapter 3 highlight
the potential use of the 3 nm GSH-Ag2Te as x-ray contrast agents due to their high x-ray
contrast and long-term safety profile.
Moreover, while the concentrations used in the experiments presented in
Chapters 2 and 3 are relevant to CT, they are higher than those used for more sensitive
imaging techniques such as fluorescence imaging. Therefore, by studying the
biocompatibility at such high concentrations in these chapters, we have highlighted the
potential of Ag2Te NPs for use in different biomedical applications requiring lower
concentrations.
Chapter 4 explored molybdenum as a new material for DEM contrast agents.
Molybdenum was previously described as a high DEM contrast-generating material.25
Yet, to date, no other group has developed molybdenum-based nanoparticles as DEM
contrast agents. In addition to their high contrast in DEM, molybdenum dichalcogenides
are considered graphene analogs with good biocompatibility and have recently received
interest in different biomedical applications.26-29 Among their various applications, limited
studies have explored MoS2 NPs as x-ray contrast agents where it is shown that MoS2
NPs can produce strong x-ray contrast due to molybdenum’s relatively high atomic
number and density. 30-33 In Chapter 4, I developed a library of 2 nm MoS2 NPs as DEMspecific contrast agents with the potential to be renally excretable. This library included 2
nm MoS2 NPs with different zwitterionic small molecules, including GSH, penicillamine,
L-cysteine, and 3-MPA, as their coatings. As mentioned above, small zwitterionic
coatings can provide stability and biocompatibility to the nanoparticles while maintaining
a small hydrodynamic diameter.3, 16-20 The design strategy used in this study to facilitate
clinical translation, aside from their small size to enable renal excretion, was to
155

incorporate different coatings and evaluate their effect on the stability and safety of the
nanoparticles. GSH- and penicillamine-coated MoS2 NPs were the most stable
formulations with no significant difference in their effect on cell viability in vitro. This
study was the first to test the cell viability of MoS2 NPs at a concentration of 1 mg/mL.
Moreover, for the first time, we quantified the in vitro contrast generation of MoS2 NPs in
DEM as compared to iopamidol, a commercially available x-ray contrast agent currently
used in clinics. Our results showed significantly higher DEM contrast, at the reported xray energies, than iopamidol and substantial CT contrast. As mentioned above, the
studies presented in Chapter 4 were the first to test the in vitro DEM contrast and
biocompatibility of MoS2 NPs, at such high concentrations. The results presented in
Chapter 4 serve as a base for the future exploration of DEM contrast agents with good xray contrast and biocompatibility.
Through this thesis, I have demonstrated the design and synthesis of Ag2Te NPs
of various sizes and desired properties and 2 nm MoS2 NPs. In addition, for the first
time, I tested the x-ray contrast of the different nanoparticles in DEM. I’ve also tested
their biocompatibility and contrast in CT. Moreover, I used several strategies to improve
their clinical translation, such as reducing their size to achieve renal excretion and using
different coatings to improve their stability, biocompatibility, and circulation time. I have
also tested the in vivo long-term biocompatibility and clearance of the renally excretable
Ag2Te NPs to facilitate their clinical translation further. The work presented further
expands the number of nanomaterials that can be used as DEM contrast agents and
aims to offer a potential solution to the current lack of DEM-specific contrast agents.
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5.2 Future directions
5.2.1 Overview
In this work, I have presented the exploration of novel materials to be used as
DEM-specific contrast agents for breast cancer screening. In addition, I’ve studied their
CT contrast and tested their biocompatibility through several assays. This section will
describe the future experiments required for their potential clinical translation and future
research on different biomedical applications for each of these nanomaterials.
Specifically, I will describe future experiments that can aid in the clinical translation of
renally clearable Ag2Te NPs and MoS2 NPs, as well as other potential biomedical
applications for these NPs. I will also describe the possible exploration of ternary silver
chalcogenide nanoparticles as DEM contrast agents. Lastly, I will describe the potential
investigation of MoTe2 nanoparticles as x-ray contrast agents.

5.2.1

Clinical translation of renally clearable Ag2Te NPs

5.2.2.1 Experiments toward the clinical translation of renally clearable Ag2Te NPs
Further studies are required to achieve clinical translation of the renally clearable
GSH-Ag2Te NPs developed in this thesis. First, the in vitro biocompatibility results
presented in Chapter 3 are limited to the assays and cell lines investigated. Thus,
broader panels of cell types should be explored in addition to more physiologically
relevant cell models, including multi-cell platforms or 3-dimensional culture of cells. Next,
the in vivo biocompatibility should be further assessed in other animal models, including
larger animals with anatomies more closely resembling humans.

Another important

parameter for the clinical translation of GSH-Ag2Te NPs as DEM contrast agents is
investigating their tumor accumulation and circulation time. A common challenge for
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ultrasmall nanoparticles is their remarkably rapid clearance from the body. If GSH-Ag2Te
NPs are cleared too rapidly, I propose loading the NPs into biodegradable polymeric
nanoparticles to improve their circulation time.13, 34 As described by Kim et al., ultrasmall
nanoparticles can be loaded into biodegradable polymeric nanoparticles for CT imaging
for enhanced contrast.13 Similarly, Higbee-Dempsey et al. described the encapsulation
of 2 nm gold nanoparticles into pH-sensitive biodegradable nanoparticles with long
circulation (3.5 h).35 The pH-sensitive micelles degraded in the acidic conditions
releasing the ultrasmall nanoparticles over time. Another important aspect for clinical
translation is its reproducibility and scale-up synthesis. After investigating in-depth the
biocompatibility and tumor accumulation of GSH-Ag2Te NPs, efforts should be made to
synthesize batches of nanoparticles of the same size and in high volumes and yield.
One strategy to reproduce uniform-sized particles in high quantities is using a
microfluidic chip to control the synthesis. The aqueous nature of the syntheses
developed in this thesis will ease and reduce upscaling costs. Microfluidic devices allow
for control over the mixing and reaction times by varying solvent flow rates or channel
geometry and by tuning the channel length since this directly corresponds to the time
taken by the reactants to flow through it.36 It also prevents the formation of large
temperature gradients possible in larger flasks owing to its larger surface area and better
heat transfer.36 Aside from the advantages of microfluidic chips in the large-scale
synthesis of reproducible nanoparticles, they can also aid in advancing in vitro assays.37,
38

For example, Farokhzad et al. developed a microfluidic chip that mimics the shear

stress in blood veins to study particle-cell interactions.39 Moreover, organs-on-a-chip and
disease-on-a-chip models have been developed to test the particle-organ interactions
and better mimic in vivo conditions.37, 38 Some of the advantages of microfluidics in the
advancement of nanoparticle clinical translation are presented in Figure 5-1. Together
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these advantages suggest the beneficial use of microfluidic devices in the clinical
translation of GSH-Ag2Te nanoparticles.

Figure 5-1: The use of microfluidic devices in the different steps of the clinical translation
of nanoparticles. Figure reproduced with permission from reference 36.

5.2.2.2 Other potential biomedical applications of renally clearable Ag2Te NPs
This thesis has focused on developing Ag2Te nanoparticles as DEM contrast
agents. However, as members of the silver chalcogenide group, Ag2Te NPs can possess
several other properties which allow their use in other biomedical applications.40 Some of
these applications include NIR fluorescence imaging, photothermal therapy, and
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biosensing.40 For example, Jin et al. have developed Ag2Te NPs with tunable size (6.5 8.1 nm) and near-infrared emission (930 – 1084 nm), high photoluminescence quantum
yields, good photostability, and low cytotoxicity used for cell labeling.41 Moreover, Dong
et al. showed that Ag2Te NPs possessed CT contrast and concentration-dependent
temperature elevation behavior under NIR irradiation with good photostability,
suggesting their use for image-guided photothermal agents for tumor hyperthermia
treatment.42 Thus, I propose further exploring the potential NIR emitting properties of
Ag2Te and their use as multimodal agents combined with other biomedical applications
to advance their potential clinical translation further.

5.2.2

Further exploration of MoS2 NPs as DEM contrast agents and future experiments
for their clinical translation
The MoS2 NPs developed in this thesis serve as a platform for their further

exploration as DEM contrast agents to detect breast cancer. We showed the DEM
contrast and biocompatibility at high concentrations of MoS2 nanoparticles with different
coatings for the first time. However, further in-depth studies exploring their in vitro and in
vivo biocompatibility are needed. To date, little research has been done on the in-depth
biocompatibility of ultrasmall MoS2 NPs, especially at CT-relevant concentrations.43-45 As
mentioned above, using strategies to better predict the in vivo interactions of cells with
different cell types would be beneficial. Therefore, I suggest performing additional
assays to evaluate the effect of MoS2 nanoparticles on the proliferation, metabolic
activity, oxidative stress, genotoxicity, and activation of immune cells of several cell
types in 2- or 3-dimension culture. Moreover, the work presented in this thesis for MoS2
NPs is focused on the in vitro exploration of the NP’s contrast and biocompatibility.
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However, while in vitro studies can serve as predictors for the in vivo behavior, these
don’t necessarily closely mimic the in vivo nanoparticle interactions with different cells
and fluids. Thus, in vivo studies on the biocompatibility and contrast of MoS2 NPs in
breast cancer tumor-bearing mice and other animals with closer anatomy to humans
would be necessary. These studies include nanoparticle accumulation in tumors, blood
circulation, and long-term biocompatibility through histology and blood chemistry assays.
Lastly, exploring the effects of the coating on the renal clearance of MoS2 NPs would be
of great interest given the limited number of research focusing on this.45, 46 This data can
provide more knowledge on the optimal coating for the future translation of MoS2 NPs.
As mentioned above, aside from the in vitro and in vivo biocompatibility assays
needed for the clinical translation of MoS2 NPs, future work could focus on the up-scale
synthesis of the nanoparticles. As with the renally clearable Ag2Te synthesis, the
aqueous nature of this synthesis leads to ease of upscaling at a lower manufacturing
cost. Therefore, strategies to reproduce and up-scale the synthesis of renally clearable
MoS2, including the use of a microfluidic chip, as described above, would be beneficial
for their clinical translation.
Lastly, future work for the further exploration of MoS2 NPs as contrast agents
could include their multimodal properties. Ultrasmall MoS2 NPs have been applied to
biomedical applications, including NIR fluorescence for imaging, cell labeling,
photoacoustic, and biosensing, primarily due to their quantum dot properties.

43-47

In

addition, larger forms of MoS2 nanomaterials have been used for drug/gene delivery,
phototherapies, and theranostics applications.28,

48, 49

A summary of the different

biomedical applications of MoS2 nanomaterials is presented in Figure 5-2. Therefore,
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exploring their application in other biomedical techniques could be beneficial for cancer
theranostics when combined with DEM breast imaging.

Figure 5-2: Summary of the different biomedical applications of MoS2 nanomaterials.
Figure adapted with permission from reference 49.

5.2.3

Exploration of other materials as DEM contrast agents
The experiments described in this thesis focused on exploring novel

nanomaterials as DEM contrast agents. Hence, I propose exploring several other novel
materials for this application as future experiments. This section will describe some of
the suggested materials to be explored as DEM-specific contrast agents.
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5.2.3.1 Ternary silver chalcogenide nanoparticles as DEM contrast agents
Ternary silver chalcogenides, including those in the I–III–VI ternary system
(AgInS2, AgInSe2, and AgInTe2), have tunable absorption, long photoluminescence
lifetime in the visible and near-infrared regions, and high quantum yields.50,

51

These

properties have allowed their exploration in biomedical applications, such as NIR
fluorescence imaging. Several synthetic approaches have been developed, yielding
size-tunable ternary silver chalcogenide nanoparticles.50-54 An example of ternary silver
chalcogenides in the size range applied in this thesis is the work reported by Tan et al.54
This group described the size-controlled synthesis of AgInS2 nanoparticles in the 3.9 to
6.3 nm core size range with good optical properties in vitro and in vivo, photostability,
and biocompatibility with HeLa cells showing the application of AgInS2 in NIR
fluorescence imaging.

While their application in NIR fluorescence imaging has been

explored, to the best of our knowledge, the x-ray imaging properties of ternary silver
chalcogenides have yet to be explored.
Indium (Z= 49), with a K-edge of 27.9 kV, is among the materials with highcontrast generation in DEM, as described in Chapter 1.25 Thus, ternary silver
chalcogenides are composed of two high-contrast generating materials for DEM in the
case of AgInS2 and AgInSe2 and three high-contrast generating materials in AgInTe2.
Therefore, these ternary silver chalcogenides can be alternative contrast agents for this
application with potentially higher contrast than primary silver chalcogenides such as
Ag2S, Ag2Se, and Ag2Te. However, ternary silver chalcogenides have not yet been
explored as DEM contrast agents. Thus, I propose the exploration of these
nanomaterials as DEM contrast agents.
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5.2.4.2 Exploration of MoTe2 as DEM contrast agents
Molybdenum ditelluride nanoparticles (MoTe2 NPs) can also be potential
alternatives as DEM contrast agents. As with Ag2Te and ternary silver chalcogenides,
MoTe2 NPs are composed of two high DEM contrast generating elements, as described
in Chapter 1.25 Both Mo and Te, with K-edges at 20.0 kV and 31.8 kV, respectively, are
well within the DEM x-ray energies used for clinical purposes. In addition, they belong to
the transition metal dichalcogenide group previously described in Chapters 1 and 4, with
numerous properties beneficial in the biomedical field. Although few syntheses have
been reported on the development of MoTe2 NPs, the chemical similarity between these
and MoS2 NPs, suggests the use of analogous chemical syntheses. For example, Ding
et al. reported an aqueous and room temperature synthesis for a library of transition
metal dichalcogenides, including MoS2 and MoTe2 QDs, using a bottom-up synthesis
and substituting the appropriate metal and chalcogenide precursors.55 Figure 5-3
summarizes the syntheses performed by Ding et al. The resulting MoTe2 QDs had a 6
nm core diameter. Still, this group presented various strategies to control the size of the
resulting QDs. Thus, I propose developing MoTe2 NPs, and for the first time, evaluating
their contrast generation in DEM and CT in addition to their in vitro and in vivo
biocompatibility.
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Figure 5-3: Bottom-up aqueous synthesis of transition metal dichalcogenide QDs. A)
Schematic of the synthesis used for the development of the QDs. B) Elements
highlighted in blue represent the transition metals, while those highlighted in orange
represent the chalcogens that could be used in this reaction to produce transition metal
dichalcogenides. Figure adapted with permission from reference 55.

5.3 Concluding remarks
This thesis described my recent work to develop novel nanomaterials as DEM
contrast agents for breast cancer screening. This work has significantly advanced the
field of DEM contrast agents and has highlighted the potential use of Ag2Te and MoS2
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NPs for this application. Moreover, by studying the long-term biocompatibility of Ag2Te
NPs and reducing their size (and that of MoS2 NPs) to achieve renal clearance, we have
made significant progress in the potential clinical translation of these nanomaterials. I am
eager to see the progression of these and alternate materials in their use as DEMspecific contrast agents and to see their clinical translation in the near future.
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